TomCl的个人主页 - 老虎社区

TomCl

TomCl

暂无个人介绍

IP属地：未知

20关注

10粉丝

0主题

0勋章

2022-01-01

Sick

1 Growth Stock Down 68% That Wall Street Thinks Could Soar in 2022

2021-12-23

Niceee nice investment and win

2021-11-12

Nixe

抱歉，原内容已删除

2021-06-25

SNDL?

Meme Stocks: How The Most Popular Have Performed in 2021

2021-06-17

$Sundial Growers Inc.(SNDL)$nice nieci

2021-06-16

Good good

Molecular Partners Announces Pricing of Initial Public Offering of American Depositary Shares in the United States

2021-06-16

Good good

Molecular Partners Announces Pricing of Initial Public Offering of American Depositary Shares in the United States

2021-06-16

Niceha

抱歉，原内容已删除

2021-06-16

Nicra

Molecular Partners Announces Pricing of Initial Public Offering of American Depositary Shares in the United States

2021-06-16

$AAL 20230120 27.0 CALL(AAL)$nnice nieci

2021-06-15

$AAL 20230120 27.0 CALL(AAL)$nnice nieci

2021-05-19

Nicely//@TomCl: Nicely

抱歉，原内容已删除

2021-05-10

Nicely

抱歉，原内容已删除

2021-05-10

Nicely

5 Unbeatable Stocks to Buy for a Biden Bull Market

2021-05-10

Nice

Cathie Wood Loads Up Another $28M Worth Of Shares In Alibaba Rival JD.Com

2021-05-06

Nice nice

2021-05-06

$Sundial Growers Inc.(SNDL)$nnice

2021-05-06

$Sundial Growers Inc.(SNDL)$nnice nieci

2021-05-05

$Sundial Growers Inc.(SNDL)$nive nice

2021-05-05

Nice nice

去老虎APP查看更多动态

{"i18n":{"language":"zh_CN"},"userPageInfo":{"id":"3571619533976102","uuid":"3571619533976102","gmtCreate":1608529903499,"gmtModify":1608956274360,"name":"TomCl","pinyin":"tomcl","introduction":"","introductionEn":"","signature":"","avatar":"https://static.tigerbbs.com/84c9633e30b56b9ef4c30ab8c67857b3","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":10,"headSize":20,"tweetSize":81,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":3,"name":"书生虎","nameTw":"書生虎","represent":"努力向上","factor":"发布10条非转发主帖,其中5条获得他人回复或点赞","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":1,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-2","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"资深虎友","description":"加入老虎社区1000天","bigImgUrl":"https://static.tigerbbs.com/0063fb68ea29c9ae6858c58630e182d5","smallImgUrl":"https://static.tigerbbs.com/96c699a93be4214d4b49aea6a5a5d1a4","grayImgUrl":"https://static.tigerbbs.com/35b0e542a9ff77046ed69ef602bc105d","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.09.17","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"02aa7f16703b4ce4ace6f1a7665789cc-3","templateUuid":"02aa7f16703b4ce4ace6f1a7665789cc","name":"知识航海家","description":"观看学堂课程满50节","bigImgUrl":"https://static.tigerbbs.com/21acbb5884e07b96522d8d84c4b7acea","smallImgUrl":"https://static.tigerbbs.com/e4e8dc2edfbfee912f4e68fe6c23b3f0","grayImgUrl":null,"redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.08.06","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":2006},{"badgeId":"228c86a078844d74991fff2b7ab2428d-3","templateUuid":"228c86a078844d74991fff2b7ab2428d","name":"投资合伙人虎","description":"证券账户累计交易金额达到100万美元","bigImgUrl":"https://static.tigerbbs.com/fbeac6bb240db7da8b972e5183d050ba","smallImgUrl":"https://static.tigerbbs.com/436cdf80292b99f0a992e78750ac4e3a","grayImgUrl":"https://static.tigerbbs.com/506a259a7b456f037592c3b23c779599","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.22","exceedPercentage":"93.37%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1101},{"badgeId":"976c19eed35f4cd78f17501c2e99ef37-1","templateUuid":"976c19eed35f4cd78f17501c2e99ef37","name":"博闻投资者","description":"累计交易超过10只正股","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"35ec162348d5460f88c959321e554969-3","templateUuid":"35ec162348d5460f88c959321e554969","name":"传说交易员","description":"证券或期货账户累计交易次数达到300次","bigImgUrl":"https://static.tigerbbs.com/656db16598a0b8f21429e10d6c1cb033","smallImgUrl":"https://static.tigerbbs.com/03f10910d4dd9234f9b5702a3342193a","grayImgUrl":"https://static.tigerbbs.com/0c767e35268feb729d50d3fa9a386c5a","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":"93.10%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":6,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":3,"crmLevelSwitch":0,"location":"未知","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":692252392,"gmtCreate":1641004346678,"gmtModify":1641004346848,"author":{"id":"3571619533976102","authorId":"3571619533976102","name":"TomCl","avatar":"https://static.tigerbbs.com/84c9633e30b56b9ef4c30ab8c67857b3","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3571619533976102","authorIdStr":"3571619533976102"},"themes":[],"htmlText":"Sick","listText":"Sick","text":"Sick","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/692252392","repostId":"2195481004","repostType":4,"repost":{"id":"2195481004","kind":"highlight","pubTimestamp":1641003960,"share":"https://www.laohu8.com/m/news/2195481004?lang=&edition=full","pubTime":"2022-01-01 10:26","market":"us","language":"en","title":"1 Growth Stock Down 68% That Wall Street Thinks Could Soar in 2022","url":"https://stock-news.laohu8.com/highlight/detail?id=2195481004","media":"Motley Fool","summary":"It poses some risks, but this company is making all the right moves to succeed in a very tough industry.","content":"<html><head></head><body><p>Let&#39;s be clear: Any stock that collapses by 68% from its high carries inherent risks, and that&#39;s certainly the case with real estate iBuying company <b><a href=\"https://laohu8.com/S/OPAD\">Offerpad Solutions</a></b> (NYSE:OPAD).</p><p>Offerpad buys homes directly from sellers, adds value by renovating them, and then flips them for a profit. It&#39;s not an easy business, as Offerpad&#39;s largest competitor, <b><a href=\"https://laohu8.com/S/Z\">Zillow</a> Group</b> (NASDAQ:Z)(NASDAQ:ZG) recently proved when it dropped out of the segment after sustaining significant losses.</p><p class=\"t-img-caption\"><img src=\"https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F659276%2Fa-smiling-couple-sitting-on-the-floor-of-their-new-home-surrounded-by-boxes.jpg&amp;w=700&amp;op=resize\" tg-width=\"700\" tg-height=\"466\" width=\"100%\" height=\"auto\"/><span>Image source: Getty Images.</span></p><p>But there are bright spots to Offerpad&#39;s different approach, and Wall Street firm JMP Securities thinks the stock has what it takes to rise by 84% in the next 12 to 18 months to $12 a share. Here&#39;s why.</p><h2>Being selective is key for Offerpad</h2><p>Since 2019, Zillow has been on a home-buying binge, purchasing 26,014 houses -- in some cases, multiple-home estates -- with the intention of reselling them quickly for a profit. This strategy is great when real estate prices are rising across the board, but when pockets of the market go soft, it can result in significant losses.</p><p>Zillow recently listed up to 1,000 of its homes for sale in its five largest markets, 64% of which were reportedly priced below what it paid for them. And in Phoenix, Arizona, up to 93% of its properties are slated to be sold at a loss. In the recent third quarter, Zillow&#39;s iBuying segment lost $244 million and erased all of the gross profit the segment had made for the entire year.</p><p>Part of the issue is Zillow&#39;s broad geographical footprint. It operates in, and therefore had to carefully track, up to 35 markets across the U.S. Offerpad, on the other hand, operates in 17 markets. Where Zillow&#39;s iBuying average gross profit per home peaked at $18,665, Offerpad&#39;s average peak (so far) is $31,500 per home in the second quarter of 2021.</p><p>It highlights the importance of being selective, because like any asset class, home prices constantly fluctuate, and being on the wrong side can be catastrophic. For Offerpad, now that its largest competitor has moved out of the way, it has an opportunity to grow its market share in the higher-quality markets Zillow has left behind.</p><h2>A surge in revenue</h2><p>By the close of 2021, Offerpad expects it will have sold up to 6,000 homes for the year, driving a record revenue result. In the recent third quarter, it actually increased its 2021 revenue guidance by $100 million. But in 2022, analysts expect it will do even better.</p><table><thead><tr><th><p>Metric</p></th><th><p>2020</p></th><th><p>2021 (Estimate)</p></th><th><p>2022 (Projected)</p></th><th><p>CAGR</p></th></tr></thead><tbody><tr><td><p>Revenue</p></td><td><p>$1.06 billion</p></td><td><p>$1.90 billion</p></td><td><p>$3.53 billion</p></td><td><p>82%</p></td></tr></tbody></table><p>Data source: Offerpad, Yahoo! Finance. CAGR = Compound Annual Growth Rate.</p><p>Offerpad&#39;s gross profit per home of $22,700 in the third quarter was down from the $31,500 it generated in the second quarter. However, it was still a 48% year-over-year gain and is therefore trending in the right direction.</p><p>The company attributes its success to a combination of its technology and people. Where other iBuying companies rely solely on algorithms to price a home, Offerpad allows technology to do 90% of the work, and it then uses physical intervention by its employees to inspect the home and bring the deal to a close.</p><p>Additionally, it adds value by renovating houses using Offerpad-employed tradespeople, which allows it to achieve higher sale prices compared to simply flipping a property immediately. The company aims to buy, renovate, and sell each home within 100 days.</p><h2>The stock is cheap</h2><p>Offerpad&#39;s stock trades at a price-to-sales multiple of just 0.8. By comparison, and despite all of its issues, Zillow&#39;s stock trades at a multiple of 2.1 based on estimated 2021 revenue. That means Offerpad&#39;s stock would need to double from here just to trade in line with its tech-real estate peer.</p><p>If Offerpad meets analysts&#39; expectations and generates $3.53 billion in revenue next year, its multiple will shrink further to just 0.4 (assuming its stock price remains the same). That makes its recent 68% decline in share price look like an attractive opportunity going into 2022.</p><p>Offerpad is expected to post a loss overall for 2021, but JMP Securities expects it will close out 2021 with a fourth-quarter profit of $0.35 per share. The firm&#39;s price target of $12 might even look conservative if Offerpad can turn profitable next year -- it&#39;s even possible it could revisit its highs near $20 per share -- but it operates in a tough business, and investors should proceed with <i>cautious </i>optimism.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>1 Growth Stock Down 68% That Wall Street Thinks Could Soar in 2022</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n1 Growth Stock Down 68% That Wall Street Thinks Could Soar in 2022\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-01-01 10:26 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/12/31/1-growth-stock-down-68-soar-2022-says-wall-street/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Let's be clear: Any stock that collapses by 68% from its high carries inherent risks, and that's certainly the case with real estate iBuying company Offerpad Solutions (NYSE:OPAD).Offerpad buys homes ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/12/31/1-growth-stock-down-68-soar-2022-says-wall-street/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4551":"寇图资本持仓","BK4548":"巴美列捷福持仓","OPAD":"Offerpad Solutions","Z":"Zillow","BK4079":"房地产服务","ZG":"Zillow Class A"},"source_url":"https://www.fool.com/investing/2021/12/31/1-growth-stock-down-68-soar-2022-says-wall-street/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2195481004","content_text":"Let's be clear: Any stock that collapses by 68% from its high carries inherent risks, and that's certainly the case with real estate iBuying company Offerpad Solutions (NYSE:OPAD).Offerpad buys homes directly from sellers, adds value by renovating them, and then flips them for a profit. It's not an easy business, as Offerpad's largest competitor, Zillow Group (NASDAQ:Z)(NASDAQ:ZG) recently proved when it dropped out of the segment after sustaining significant losses.Image source: Getty Images.But there are bright spots to Offerpad's different approach, and Wall Street firm JMP Securities thinks the stock has what it takes to rise by 84% in the next 12 to 18 months to $12 a share. Here's why.Being selective is key for OfferpadSince 2019, Zillow has been on a home-buying binge, purchasing 26,014 houses -- in some cases, multiple-home estates -- with the intention of reselling them quickly for a profit. This strategy is great when real estate prices are rising across the board, but when pockets of the market go soft, it can result in significant losses.Zillow recently listed up to 1,000 of its homes for sale in its five largest markets, 64% of which were reportedly priced below what it paid for them. And in Phoenix, Arizona, up to 93% of its properties are slated to be sold at a loss. In the recent third quarter, Zillow's iBuying segment lost $244 million and erased all of the gross profit the segment had made for the entire year.Part of the issue is Zillow's broad geographical footprint. It operates in, and therefore had to carefully track, up to 35 markets across the U.S. Offerpad, on the other hand, operates in 17 markets. Where Zillow's iBuying average gross profit per home peaked at $18,665, Offerpad's average peak (so far) is $31,500 per home in the second quarter of 2021.It highlights the importance of being selective, because like any asset class, home prices constantly fluctuate, and being on the wrong side can be catastrophic. For Offerpad, now that its largest competitor has moved out of the way, it has an opportunity to grow its market share in the higher-quality markets Zillow has left behind.A surge in revenueBy the close of 2021, Offerpad expects it will have sold up to 6,000 homes for the year, driving a record revenue result. In the recent third quarter, it actually increased its 2021 revenue guidance by $100 million. But in 2022, analysts expect it will do even better.Metric20202021 (Estimate)2022 (Projected)CAGRRevenue$1.06 billion$1.90 billion$3.53 billion82%Data source: Offerpad, Yahoo! Finance. CAGR = Compound Annual Growth Rate.Offerpad's gross profit per home of $22,700 in the third quarter was down from the $31,500 it generated in the second quarter. However, it was still a 48% year-over-year gain and is therefore trending in the right direction.The company attributes its success to a combination of its technology and people. Where other iBuying companies rely solely on algorithms to price a home, Offerpad allows technology to do 90% of the work, and it then uses physical intervention by its employees to inspect the home and bring the deal to a close.Additionally, it adds value by renovating houses using Offerpad-employed tradespeople, which allows it to achieve higher sale prices compared to simply flipping a property immediately. The company aims to buy, renovate, and sell each home within 100 days.The stock is cheapOfferpad's stock trades at a price-to-sales multiple of just 0.8. By comparison, and despite all of its issues, Zillow's stock trades at a multiple of 2.1 based on estimated 2021 revenue. That means Offerpad's stock would need to double from here just to trade in line with its tech-real estate peer.If Offerpad meets analysts' expectations and generates $3.53 billion in revenue next year, its multiple will shrink further to just 0.4 (assuming its stock price remains the same). That makes its recent 68% decline in share price look like an attractive opportunity going into 2022.Offerpad is expected to post a loss overall for 2021, but JMP Securities expects it will close out 2021 with a fourth-quarter profit of $0.35 per share. The firm's price target of $12 might even look conservative if Offerpad can turn profitable next year -- it's even possible it could revisit its highs near $20 per share -- but it operates in a tough business, and investors should proceed with cautious optimism.","news_type":1},"isVote":1,"tweetType":1,"viewCount":680,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":698018419,"gmtCreate":1640260145346,"gmtModify":1640260145486,"author":{"id":"3571619533976102","authorId":"3571619533976102","name":"TomCl","avatar":"https://static.tigerbbs.com/84c9633e30b56b9ef4c30ab8c67857b3","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3571619533976102","authorIdStr":"3571619533976102"},"themes":[],"htmlText":"Niceee nice investment and win","listText":"Niceee nice investment and win","text":"Niceee nice investment and win","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/698018419","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":879655778,"gmtCreate":1636721723200,"gmtModify":1636721723314,"author":{"id":"3571619533976102","authorId":"3571619533976102","name":"TomCl","avatar":"https://static.tigerbbs.com/84c9633e30b56b9ef4c30ab8c67857b3","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3571619533976102","authorIdStr":"3571619533976102"},"themes":[],"htmlText":"Nixe","listText":"Nixe","text":"Nixe","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/879655778","repostId":"2163488152","repostType":2,"isVote":1,"tweetType":1,"viewCount":720,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":122955354,"gmtCreate":1624594640978,"gmtModify":1631890890036,"author":{"id":"3571619533976102","authorId":"3571619533976102","name":"TomCl","avatar":"https://static.tigerbbs.com/84c9633e30b56b9ef4c30ab8c67857b3","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3571619533976102","authorIdStr":"3571619533976102"},"themes":[],"htmlText":"SNDL?","listText":"SNDL?","text":"SNDL?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/122955354","repostId":"1147153207","repostType":4,"repost":{"id":"1147153207","kind":"news","pubTimestamp":1624592020,"share":"https://www.laohu8.com/m/news/1147153207?lang=&edition=full","pubTime":"2021-06-25 11:33","market":"us","language":"en","title":"Meme Stocks: How The Most Popular Have Performed in 2021","url":"https://stock-news.laohu8.com/highlight/detail?id=1147153207","media":"thestreet","summary":"Meme mania has been one of the most unexpected phenomena in the equities market in an already atypic","content":"<p>Meme mania has been one of the most unexpected phenomena in the equities market in an already atypical pandemic environment. The “meme attacks” have rarely been based on business fundamentals, but instead fueled by momentum and discussions on web forums that catalyze vicious rallies.</p>\n<p>Below, the Wall Street Memes channel lists some of the most popular meme stocks and how each has performed so far in 2021.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/ac11607753df2d587eff881c858546dd\" tg-width=\"1200\" tg-height=\"798\" referrerpolicy=\"no-referrer\"><span>Figure 1: GameStop store.</span></p>\n<p><b>GME - GameStop Corp.</b></p>\n<ul>\n <li>Largest gain in 2021:<b>1,914%</b></li>\n <li>Largest loss in 2021:<b>-88%</b></li>\n <li>Peak price:<b>$347.51</b></li>\n <li>Current price:<b>$200.18</b>(at last check).</li>\n</ul>\n<p><img src=\"https://static.tigerbbs.com/cc5e113c20912daf07551e09179fe9f2\" tg-width=\"1200\" tg-height=\"519\" referrerpolicy=\"no-referrer\"><b>AMC - AMC Theaters</b></p>\n<ul>\n <li>Largest gain in 2021:<b>2,850%</b></li>\n <li>Largest loss in 2021:<b>-72%</b></li>\n <li>Peak price:<b>$62.55</b></li>\n <li>Current price:<b>$55.14</b>(at last check).</li>\n</ul>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/2e55df7c82d93174a0b4c088c17946a1\" tg-width=\"1200\" tg-height=\"533\" referrerpolicy=\"no-referrer\"><span>Google Finance</span></p>\n<p><b>BB - BlackBerry Limited</b></p>\n<ul>\n <li>Largest gain in 2021:<b>281%</b></li>\n <li>Largest loss in 2021:<b>-68%</b></li>\n <li>Peak price:<b>$25.10</b></li>\n <li>Current price:<b>$12.82</b>(at last check).</li>\n</ul>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/00f988c9dcc4545d783ac29b2061f44d\" tg-width=\"1200\" tg-height=\"525\" referrerpolicy=\"no-referrer\"><span>Google Finance</span></p>\n<p><b>CLNE - Clean Energy Fuels Corp.</b></p>\n<ul>\n <li>Largest gain in 2021:<b>137%</b></li>\n <li>Largest loss in 2021:<b>-59%</b></li>\n <li>Peak price:<b>$18.64</b></li>\n <li>Current price:<b>$11.22</b>(at last check).</li>\n</ul>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/42e24ea5dd3ca3f186eab5451fa7fcbc\" tg-width=\"1200\" tg-height=\"524\" referrerpolicy=\"no-referrer\"><span>Google Finance</span></p>\n<p><b>CLOV - Clover Health Investments</b></p>\n<ul>\n <li>Largest gain in 2021:<b>224%</b></li>\n <li>Largest loss in 2021:<b>-56%</b></li>\n <li>Peak price:<b>$22.15</b></li>\n <li>Current price:<b>$12.10</b>(at last check).</li>\n</ul>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/ddfd7742b5b929d9febee80c5926f08f\" tg-width=\"1200\" tg-height=\"507\" referrerpolicy=\"no-referrer\"><span>Google Finance</span></p>\n<p><b>CLF - Cleveland-Cliff</b></p>\n<ul>\n <li>Largest gain in 2021:<b>83%</b></li>\n <li>Largest loss in 2021:<b>-28%</b></li>\n <li>Peak price:<b>$24.44</b></li>\n <li>Current price:<b>$20.75</b>(at last check).</li>\n</ul>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/15c8accc6baf5e68f5a1088eb8a75c4d\" tg-width=\"1200\" tg-height=\"524\" referrerpolicy=\"no-referrer\"><span>Google Finance</span></p>\n<p><b>TLRY - Tilray Pharmaceuticals</b></p>\n<ul>\n <li>Largest gain in 2021:<b>610%</b></li>\n <li>Largest loss in 2021:<b>-78%</b></li>\n <li>Peak price:<b>$63.91</b></li>\n <li>Current price:<b>$17.23</b>(at last check).</li>\n</ul>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/dc9ed19b51e752ceff9a6534d4afd089\" tg-width=\"1200\" tg-height=\"510\" referrerpolicy=\"no-referrer\"><span>Google Finance</span></p>\n<p><b>NOK - Nokia Corporation</b></p>\n<ul>\n <li>Largest gain in 2021:<b>69%</b></li>\n <li>Largest loss in 2021:<b>-41%</b></li>\n <li>Peak price:<b>$6.55</b></li>\n <li>Current price:<b>$5.14</b>(at last check).</li>\n</ul>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/33e920e940ac016540520a46acbcb0d5\" tg-width=\"1200\" tg-height=\"511\" referrerpolicy=\"no-referrer\"><span>Google Finance</span></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Meme Stocks: How The Most Popular Have Performed in 2021</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMeme Stocks: How The Most Popular Have Performed in 2021\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-25 11:33 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.thestreet.com/memestocks/other-memes/meme-stocks-how-the-most-popular-have-performed-in-2021><strong>thestreet</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Meme mania has been one of the most unexpected phenomena in the equities market in an already atypical pandemic environment. The “meme attacks” have rarely been based on business fundamentals, but ...</p>\n\n<a href=\"https://www.thestreet.com/memestocks/other-memes/meme-stocks-how-the-most-popular-have-performed-in-2021\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NOK":"诺基亚","TLRY":"Tilray Inc.","GME":"游戏驿站","BB":"黑莓","AMC":"AMC院线","CLF":"克利夫兰克里夫","CLNE":"Clean Energy Fuels Corp","CLOV":"Clover Health Corp"},"source_url":"https://www.thestreet.com/memestocks/other-memes/meme-stocks-how-the-most-popular-have-performed-in-2021","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1147153207","content_text":"Meme mania has been one of the most unexpected phenomena in the equities market in an already atypical pandemic environment. The “meme attacks” have rarely been based on business fundamentals, but instead fueled by momentum and discussions on web forums that catalyze vicious rallies.\nBelow, the Wall Street Memes channel lists some of the most popular meme stocks and how each has performed so far in 2021.\nFigure 1: GameStop store.\nGME - GameStop Corp.\n\nLargest gain in 2021:1,914%\nLargest loss in 2021:-88%\nPeak price:$347.51\nCurrent price:$200.18(at last check).\n\nAMC - AMC Theaters\n\nLargest gain in 2021:2,850%\nLargest loss in 2021:-72%\nPeak price:$62.55\nCurrent price:$55.14(at last check).\n\nGoogle Finance\nBB - BlackBerry Limited\n\nLargest gain in 2021:281%\nLargest loss in 2021:-68%\nPeak price:$25.10\nCurrent price:$12.82(at last check).\n\nGoogle Finance\nCLNE - Clean Energy Fuels Corp.\n\nLargest gain in 2021:137%\nLargest loss in 2021:-59%\nPeak price:$18.64\nCurrent price:$11.22(at last check).\n\nGoogle Finance\nCLOV - Clover Health Investments\n\nLargest gain in 2021:224%\nLargest loss in 2021:-56%\nPeak price:$22.15\nCurrent price:$12.10(at last check).\n\nGoogle Finance\nCLF - Cleveland-Cliff\n\nLargest gain in 2021:83%\nLargest loss in 2021:-28%\nPeak price:$24.44\nCurrent price:$20.75(at last check).\n\nGoogle Finance\nTLRY - Tilray Pharmaceuticals\n\nLargest gain in 2021:610%\nLargest loss in 2021:-78%\nPeak price:$63.91\nCurrent price:$17.23(at last check).\n\nGoogle Finance\nNOK - Nokia Corporation\n\nLargest gain in 2021:69%\nLargest loss in 2021:-41%\nPeak price:$6.55\nCurrent price:$5.14(at last check).\n\nGoogle Finance","news_type":1},"isVote":1,"tweetType":1,"viewCount":496,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":161221259,"gmtCreate":1623929962671,"gmtModify":1631890890041,"author":{"id":"3571619533976102","authorId":"3571619533976102","name":"TomCl","avatar":"https://static.tigerbbs.com/84c9633e30b56b9ef4c30ab8c67857b3","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3571619533976102","authorIdStr":"3571619533976102"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/SNDL\">$Sundial Growers Inc.(SNDL)$</a>nice nieci","listText":"<a href=\"https://laohu8.com/S/SNDL\">$Sundial Growers Inc.(SNDL)$</a>nice nieci","text":"$Sundial Growers Inc.(SNDL)$nice nieci","images":[{"img":"https://static.tigerbbs.com/fab74b2cd1a99b5693d5411f077730f3","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/161221259","isVote":1,"tweetType":1,"viewCount":469,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":163050271,"gmtCreate":1623854239793,"gmtModify":1631890890041,"author":{"id":"3571619533976102","authorId":"3571619533976102","name":"TomCl","avatar":"https://static.tigerbbs.com/84c9633e30b56b9ef4c30ab8c67857b3","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3571619533976102","authorIdStr":"3571619533976102"},"themes":[],"htmlText":"Good good","listText":"Good good","text":"Good good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/163050271","repostId":"2143879474","repostType":4,"repost":{"id":"2143879474","kind":"news","pubTimestamp":1623853920,"share":"https://www.laohu8.com/m/news/2143879474?lang=&edition=full","pubTime":"2021-06-16 22:32","market":"us","language":"en","title":"Molecular Partners Announces Pricing of Initial Public Offering of American Depositary Shares in the United States","url":"https://stock-news.laohu8.com/highlight/detail?id=2143879474","media":"ACCESSWIRE","summary":"ZURICH-SCHLIEREN, SWITZERLAND / ACCESSWIRE / June 15, 2021 / Molecular Partners AG (SIX:MOLN), a cli","content":"<p><b>ZURICH-SCHLIEREN, SWITZERLAND / ACCESSWIRE / June 15, 2021 / </b><a href=\"https://laohu8.com/S/MOLN\">Molecular Partners AG</a> (SIX:MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin® therapeutics, today announced the pricing of its initial public offering in the United States of 3,000,000 American Depositary Shares ('ADSs') at a public offering price of $21.25 per ADS, for total gross proceeds of approximately $63.8 million. All ADSs sold in the offering were offered by Molecular Partners. Each ADS will represent <a href=\"https://laohu8.com/S/AONE\">one</a> Molecular Partners ordinary share. The new ordinary shares underlying the ADSs will be issued from Molecular Partners' authorized capital under exclusion of the existing shareholders' pre-emptive rights. In addition, Molecular Partners has granted the underwriters a 30-day option to purchase up to an additional 450,000 ADSs at the initial public offering price, less underwriting discounts and commissions.</p>\n<p>Trading of the ADSs is expected to commence on The Nasdaq Global Select Market on Wednesday, June 16, 2021 under the ticker symbol 'MOLN.' SIX Swiss Exchange ('SIX') approved the listing of the new ordinary shares underlying the ADSs as of June 17, 2021.</p>\n<p>On June 16, 2021, trading of the existing shares of Molecular Partners on SIX will be halted. If trading of the ADS on the Nasdaq will commence at 4 p.m. CEST on June 16, 2021 or any time before, trading of the shares of Molecular Partners on SIX will reopen on the same day. If trading on the Nasdaq starts later, trading of the shares in Molecular Partners on SIX will reopen on June 17, 2021 only.</p>\n<p>The offering is expected to close on or about June 18, 2021, subject to customary closing conditions.</p>\n<p>J.P. Morgan, SVB Leerink and Cowen are acting as joint book-running managers for the proposed offering. RBC Capital Markets is acting as the bookrunner for the proposed offering. Kempen &amp; Co is acting as the lead manager for the proposed offering.</p>\n<p>A registration statement on Form F-1 relating to these securities became effective on June 15, 2021. The securities referred to in this release are to be offered only by means of a prospectus. Copies of the final prospectus relating to the offering may be obtained, when available, for free by visiting EDGAR on the SEC website at www.sec.gov. Alternatively, a written copy may be obtained for free from J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717, telephone: 1-866-803-9204; SVB Leerink LLC, Attention: Syndicate Department, One Federal Street, 37th Floor, Boston, MA 02110, by telephone at 1-800-808-7525, ext. 6105, or by e-mailing syndicate@svbleerink.com; Cowen and Company, LLC (c/o Broadridge Financial Services), 1155 Long Island Avenue, Edgewood, NY, 11717, Attn: Prospectus Department, by telephone at (833) 297-2926 or by email at PostSaleManualRequests@broadridge.com. The securities may not be sold, nor may offers to buy be accepted, prior to the time the registration statement becomes effective. In connection with the listing of the ordinary shares on the SIX, the registration statement on Form F-1 constitutes a foreign prospectus within the meaning of article 54 paras. 2 and 3 of the Swiss Financial Services Act of June 15, 2018 ('FinSA') and article 70 paras. 2-4 of the Swiss Financial Services Ordinance of November 6, 2019 ('FinSO'). The registration statement on Form F-1, including the preliminary prospectus, as well as the final prospectus, once available, will be deposited with the Prospectus Office of SIX Exchange Regulation. Further, the inclusion of the foreign prospectus in the prospectus list published by the Prospectus Office of SIX Exchange Regulation will be requested.</p>\n<p>This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. There is no intention or permission to publicly offer, solicit, sell or advertise, directly or indirectly, any securities of Molecular Partners in or into Switzerland within the meaning of FinSA.</p>\n<h4>About Molecular Partners AG</h4>\n<p>Molecular Partners AG is a clinical-stage biotech company developing DARPin® therapeutics, a new class of custom-built protein drugs designed to address challenges current modalities cannot. The Company has formed partnerships with leading pharmaceutical companies to advance DARPin® therapeutics in the areas of ophthalmology, oncology and infectious disease, and has compounds in various stages of clinical and preclinical development across multiple therapeutic areas.</p>","source":"yahoofinance","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Molecular Partners Announces Pricing of Initial Public Offering of American Depositary Shares in the United States</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMolecular Partners Announces Pricing of Initial Public Offering of American Depositary Shares in the United States\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-16 22:32 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/molecular-partners-announces-pricing-initial-020000537.html><strong>ACCESSWIRE</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>ZURICH-SCHLIEREN, SWITZERLAND / ACCESSWIRE / June 15, 2021 / Molecular Partners AG (SIX:MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin® ...</p>\n\n<a href=\"https://finance.yahoo.com/news/molecular-partners-announces-pricing-initial-020000537.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"UBCP":"联合合众银行","AFG":"美国金融集团有限公司","MOLN":"Molecular Partners AG","00626":"大众金融控股","00467":"联合能源集团"},"source_url":"https://finance.yahoo.com/news/molecular-partners-announces-pricing-initial-020000537.html","is_english":true,"share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","article_id":"2143879474","content_text":"ZURICH-SCHLIEREN, SWITZERLAND / ACCESSWIRE / June 15, 2021 / Molecular Partners AG (SIX:MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin® therapeutics, today announced the pricing of its initial public offering in the United States of 3,000,000 American Depositary Shares ('ADSs') at a public offering price of $21.25 per ADS, for total gross proceeds of approximately $63.8 million. All ADSs sold in the offering were offered by Molecular Partners. Each ADS will represent one Molecular Partners ordinary share. The new ordinary shares underlying the ADSs will be issued from Molecular Partners' authorized capital under exclusion of the existing shareholders' pre-emptive rights. In addition, Molecular Partners has granted the underwriters a 30-day option to purchase up to an additional 450,000 ADSs at the initial public offering price, less underwriting discounts and commissions.\nTrading of the ADSs is expected to commence on The Nasdaq Global Select Market on Wednesday, June 16, 2021 under the ticker symbol 'MOLN.' SIX Swiss Exchange ('SIX') approved the listing of the new ordinary shares underlying the ADSs as of June 17, 2021.\nOn June 16, 2021, trading of the existing shares of Molecular Partners on SIX will be halted. If trading of the ADS on the Nasdaq will commence at 4 p.m. CEST on June 16, 2021 or any time before, trading of the shares of Molecular Partners on SIX will reopen on the same day. If trading on the Nasdaq starts later, trading of the shares in Molecular Partners on SIX will reopen on June 17, 2021 only.\nThe offering is expected to close on or about June 18, 2021, subject to customary closing conditions.\nJ.P. Morgan, SVB Leerink and Cowen are acting as joint book-running managers for the proposed offering. RBC Capital Markets is acting as the bookrunner for the proposed offering. Kempen & Co is acting as the lead manager for the proposed offering.\nA registration statement on Form F-1 relating to these securities became effective on June 15, 2021. The securities referred to in this release are to be offered only by means of a prospectus. Copies of the final prospectus relating to the offering may be obtained, when available, for free by visiting EDGAR on the SEC website at www.sec.gov. Alternatively, a written copy may be obtained for free from J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717, telephone: 1-866-803-9204; SVB Leerink LLC, Attention: Syndicate Department, One Federal Street, 37th Floor, Boston, MA 02110, by telephone at 1-800-808-7525, ext. 6105, or by e-mailing syndicate@svbleerink.com; Cowen and Company, LLC (c/o Broadridge Financial Services), 1155 Long Island Avenue, Edgewood, NY, 11717, Attn: Prospectus Department, by telephone at (833) 297-2926 or by email at PostSaleManualRequests@broadridge.com. The securities may not be sold, nor may offers to buy be accepted, prior to the time the registration statement becomes effective. In connection with the listing of the ordinary shares on the SIX, the registration statement on Form F-1 constitutes a foreign prospectus within the meaning of article 54 paras. 2 and 3 of the Swiss Financial Services Act of June 15, 2018 ('FinSA') and article 70 paras. 2-4 of the Swiss Financial Services Ordinance of November 6, 2019 ('FinSO'). The registration statement on Form F-1, including the preliminary prospectus, as well as the final prospectus, once available, will be deposited with the Prospectus Office of SIX Exchange Regulation. Further, the inclusion of the foreign prospectus in the prospectus list published by the Prospectus Office of SIX Exchange Regulation will be requested.\nThis press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. There is no intention or permission to publicly offer, solicit, sell or advertise, directly or indirectly, any securities of Molecular Partners in or into Switzerland within the meaning of FinSA.\nAbout Molecular Partners AG\nMolecular Partners AG is a clinical-stage biotech company developing DARPin® therapeutics, a new class of custom-built protein drugs designed to address challenges current modalities cannot. The Company has formed partnerships with leading pharmaceutical companies to advance DARPin® therapeutics in the areas of ophthalmology, oncology and infectious disease, and has compounds in various stages of clinical and preclinical development across multiple therapeutic areas.","news_type":1},"isVote":1,"tweetType":1,"viewCount":247,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":163027475,"gmtCreate":1623854226797,"gmtModify":1631890890044,"author":{"id":"3571619533976102","authorId":"3571619533976102","name":"TomCl","avatar":"https://static.tigerbbs.com/84c9633e30b56b9ef4c30ab8c67857b3","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3571619533976102","authorIdStr":"3571619533976102"},"themes":[],"htmlText":"Good good","listText":"Good good","text":"Good good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/163027475","repostId":"2143879474","repostType":4,"repost":{"id":"2143879474","kind":"news","pubTimestamp":1623853920,"share":"https://www.laohu8.com/m/news/2143879474?lang=&edition=full","pubTime":"2021-06-16 22:32","market":"us","language":"en","title":"Molecular Partners Announces Pricing of Initial Public Offering of American Depositary Shares in the United States","url":"https://stock-news.laohu8.com/highlight/detail?id=2143879474","media":"ACCESSWIRE","summary":"ZURICH-SCHLIEREN, SWITZERLAND / ACCESSWIRE / June 15, 2021 / Molecular Partners AG (SIX:MOLN), a cli","content":"<p><b>ZURICH-SCHLIEREN, SWITZERLAND / ACCESSWIRE / June 15, 2021 / </b><a href=\"https://laohu8.com/S/MOLN\">Molecular Partners AG</a> (SIX:MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin® therapeutics, today announced the pricing of its initial public offering in the United States of 3,000,000 American Depositary Shares ('ADSs') at a public offering price of $21.25 per ADS, for total gross proceeds of approximately $63.8 million. All ADSs sold in the offering were offered by Molecular Partners. Each ADS will represent <a href=\"https://laohu8.com/S/AONE\">one</a> Molecular Partners ordinary share. The new ordinary shares underlying the ADSs will be issued from Molecular Partners' authorized capital under exclusion of the existing shareholders' pre-emptive rights. In addition, Molecular Partners has granted the underwriters a 30-day option to purchase up to an additional 450,000 ADSs at the initial public offering price, less underwriting discounts and commissions.</p>\n<p>Trading of the ADSs is expected to commence on The Nasdaq Global Select Market on Wednesday, June 16, 2021 under the ticker symbol 'MOLN.' SIX Swiss Exchange ('SIX') approved the listing of the new ordinary shares underlying the ADSs as of June 17, 2021.</p>\n<p>On June 16, 2021, trading of the existing shares of Molecular Partners on SIX will be halted. If trading of the ADS on the Nasdaq will commence at 4 p.m. CEST on June 16, 2021 or any time before, trading of the shares of Molecular Partners on SIX will reopen on the same day. If trading on the Nasdaq starts later, trading of the shares in Molecular Partners on SIX will reopen on June 17, 2021 only.</p>\n<p>The offering is expected to close on or about June 18, 2021, subject to customary closing conditions.</p>\n<p>J.P. Morgan, SVB Leerink and Cowen are acting as joint book-running managers for the proposed offering. RBC Capital Markets is acting as the bookrunner for the proposed offering. Kempen &amp; Co is acting as the lead manager for the proposed offering.</p>\n<p>A registration statement on Form F-1 relating to these securities became effective on June 15, 2021. The securities referred to in this release are to be offered only by means of a prospectus. Copies of the final prospectus relating to the offering may be obtained, when available, for free by visiting EDGAR on the SEC website at www.sec.gov. Alternatively, a written copy may be obtained for free from J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717, telephone: 1-866-803-9204; SVB Leerink LLC, Attention: Syndicate Department, One Federal Street, 37th Floor, Boston, MA 02110, by telephone at 1-800-808-7525, ext. 6105, or by e-mailing syndicate@svbleerink.com; Cowen and Company, LLC (c/o Broadridge Financial Services), 1155 Long Island Avenue, Edgewood, NY, 11717, Attn: Prospectus Department, by telephone at (833) 297-2926 or by email at PostSaleManualRequests@broadridge.com. The securities may not be sold, nor may offers to buy be accepted, prior to the time the registration statement becomes effective. In connection with the listing of the ordinary shares on the SIX, the registration statement on Form F-1 constitutes a foreign prospectus within the meaning of article 54 paras. 2 and 3 of the Swiss Financial Services Act of June 15, 2018 ('FinSA') and article 70 paras. 2-4 of the Swiss Financial Services Ordinance of November 6, 2019 ('FinSO'). The registration statement on Form F-1, including the preliminary prospectus, as well as the final prospectus, once available, will be deposited with the Prospectus Office of SIX Exchange Regulation. Further, the inclusion of the foreign prospectus in the prospectus list published by the Prospectus Office of SIX Exchange Regulation will be requested.</p>\n<p>This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. There is no intention or permission to publicly offer, solicit, sell or advertise, directly or indirectly, any securities of Molecular Partners in or into Switzerland within the meaning of FinSA.</p>\n<h4>About Molecular Partners AG</h4>\n<p>Molecular Partners AG is a clinical-stage biotech company developing DARPin® therapeutics, a new class of custom-built protein drugs designed to address challenges current modalities cannot. The Company has formed partnerships with leading pharmaceutical companies to advance DARPin® therapeutics in the areas of ophthalmology, oncology and infectious disease, and has compounds in various stages of clinical and preclinical development across multiple therapeutic areas.</p>","source":"yahoofinance","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Molecular Partners Announces Pricing of Initial Public Offering of American Depositary Shares in the United States</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMolecular Partners Announces Pricing of Initial Public Offering of American Depositary Shares in the United States\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-16 22:32 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/molecular-partners-announces-pricing-initial-020000537.html><strong>ACCESSWIRE</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>ZURICH-SCHLIEREN, SWITZERLAND / ACCESSWIRE / June 15, 2021 / Molecular Partners AG (SIX:MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin® ...</p>\n\n<a href=\"https://finance.yahoo.com/news/molecular-partners-announces-pricing-initial-020000537.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"UBCP":"联合合众银行","AFG":"美国金融集团有限公司","MOLN":"Molecular Partners AG","00626":"大众金融控股","00467":"联合能源集团"},"source_url":"https://finance.yahoo.com/news/molecular-partners-announces-pricing-initial-020000537.html","is_english":true,"share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","article_id":"2143879474","content_text":"ZURICH-SCHLIEREN, SWITZERLAND / ACCESSWIRE / June 15, 2021 / Molecular Partners AG (SIX:MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin® therapeutics, today announced the pricing of its initial public offering in the United States of 3,000,000 American Depositary Shares ('ADSs') at a public offering price of $21.25 per ADS, for total gross proceeds of approximately $63.8 million. All ADSs sold in the offering were offered by Molecular Partners. Each ADS will represent one Molecular Partners ordinary share. The new ordinary shares underlying the ADSs will be issued from Molecular Partners' authorized capital under exclusion of the existing shareholders' pre-emptive rights. In addition, Molecular Partners has granted the underwriters a 30-day option to purchase up to an additional 450,000 ADSs at the initial public offering price, less underwriting discounts and commissions.\nTrading of the ADSs is expected to commence on The Nasdaq Global Select Market on Wednesday, June 16, 2021 under the ticker symbol 'MOLN.' SIX Swiss Exchange ('SIX') approved the listing of the new ordinary shares underlying the ADSs as of June 17, 2021.\nOn June 16, 2021, trading of the existing shares of Molecular Partners on SIX will be halted. If trading of the ADS on the Nasdaq will commence at 4 p.m. CEST on June 16, 2021 or any time before, trading of the shares of Molecular Partners on SIX will reopen on the same day. If trading on the Nasdaq starts later, trading of the shares in Molecular Partners on SIX will reopen on June 17, 2021 only.\nThe offering is expected to close on or about June 18, 2021, subject to customary closing conditions.\nJ.P. Morgan, SVB Leerink and Cowen are acting as joint book-running managers for the proposed offering. RBC Capital Markets is acting as the bookrunner for the proposed offering. Kempen & Co is acting as the lead manager for the proposed offering.\nA registration statement on Form F-1 relating to these securities became effective on June 15, 2021. The securities referred to in this release are to be offered only by means of a prospectus. Copies of the final prospectus relating to the offering may be obtained, when available, for free by visiting EDGAR on the SEC website at www.sec.gov. Alternatively, a written copy may be obtained for free from J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717, telephone: 1-866-803-9204; SVB Leerink LLC, Attention: Syndicate Department, One Federal Street, 37th Floor, Boston, MA 02110, by telephone at 1-800-808-7525, ext. 6105, or by e-mailing syndicate@svbleerink.com; Cowen and Company, LLC (c/o Broadridge Financial Services), 1155 Long Island Avenue, Edgewood, NY, 11717, Attn: Prospectus Department, by telephone at (833) 297-2926 or by email at PostSaleManualRequests@broadridge.com. The securities may not be sold, nor may offers to buy be accepted, prior to the time the registration statement becomes effective. In connection with the listing of the ordinary shares on the SIX, the registration statement on Form F-1 constitutes a foreign prospectus within the meaning of article 54 paras. 2 and 3 of the Swiss Financial Services Act of June 15, 2018 ('FinSA') and article 70 paras. 2-4 of the Swiss Financial Services Ordinance of November 6, 2019 ('FinSO'). The registration statement on Form F-1, including the preliminary prospectus, as well as the final prospectus, once available, will be deposited with the Prospectus Office of SIX Exchange Regulation. Further, the inclusion of the foreign prospectus in the prospectus list published by the Prospectus Office of SIX Exchange Regulation will be requested.\nThis press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. There is no intention or permission to publicly offer, solicit, sell or advertise, directly or indirectly, any securities of Molecular Partners in or into Switzerland within the meaning of FinSA.\nAbout Molecular Partners AG\nMolecular Partners AG is a clinical-stage biotech company developing DARPin® therapeutics, a new class of custom-built protein drugs designed to address challenges current modalities cannot. The Company has formed partnerships with leading pharmaceutical companies to advance DARPin® therapeutics in the areas of ophthalmology, oncology and infectious disease, and has compounds in various stages of clinical and preclinical development across multiple therapeutic areas.","news_type":1},"isVote":1,"tweetType":1,"viewCount":292,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":163027172,"gmtCreate":1623854206696,"gmtModify":1631890890047,"author":{"id":"3571619533976102","authorId":"3571619533976102","name":"TomCl","avatar":"https://static.tigerbbs.com/84c9633e30b56b9ef4c30ab8c67857b3","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3571619533976102","authorIdStr":"3571619533976102"},"themes":[],"htmlText":"Niceha","listText":"Niceha","text":"Niceha","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/163027172","repostId":"1109608534","repostType":4,"isVote":1,"tweetType":1,"viewCount":207,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":163024709,"gmtCreate":1623854195601,"gmtModify":1631890890052,"author":{"id":"3571619533976102","authorId":"3571619533976102","name":"TomCl","avatar":"https://static.tigerbbs.com/84c9633e30b56b9ef4c30ab8c67857b3","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3571619533976102","authorIdStr":"3571619533976102"},"themes":[],"htmlText":"Nicra","listText":"Nicra","text":"Nicra","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/163024709","repostId":"2143879474","repostType":4,"repost":{"id":"2143879474","kind":"news","pubTimestamp":1623853920,"share":"https://www.laohu8.com/m/news/2143879474?lang=&edition=full","pubTime":"2021-06-16 22:32","market":"us","language":"en","title":"Molecular Partners Announces Pricing of Initial Public Offering of American Depositary Shares in the United States","url":"https://stock-news.laohu8.com/highlight/detail?id=2143879474","media":"ACCESSWIRE","summary":"ZURICH-SCHLIEREN, SWITZERLAND / ACCESSWIRE / June 15, 2021 / Molecular Partners AG (SIX:MOLN), a cli","content":"<p><b>ZURICH-SCHLIEREN, SWITZERLAND / ACCESSWIRE / June 15, 2021 / </b><a href=\"https://laohu8.com/S/MOLN\">Molecular Partners AG</a> (SIX:MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin® therapeutics, today announced the pricing of its initial public offering in the United States of 3,000,000 American Depositary Shares ('ADSs') at a public offering price of $21.25 per ADS, for total gross proceeds of approximately $63.8 million. All ADSs sold in the offering were offered by Molecular Partners. Each ADS will represent <a href=\"https://laohu8.com/S/AONE\">one</a> Molecular Partners ordinary share. The new ordinary shares underlying the ADSs will be issued from Molecular Partners' authorized capital under exclusion of the existing shareholders' pre-emptive rights. In addition, Molecular Partners has granted the underwriters a 30-day option to purchase up to an additional 450,000 ADSs at the initial public offering price, less underwriting discounts and commissions.</p>\n<p>Trading of the ADSs is expected to commence on The Nasdaq Global Select Market on Wednesday, June 16, 2021 under the ticker symbol 'MOLN.' SIX Swiss Exchange ('SIX') approved the listing of the new ordinary shares underlying the ADSs as of June 17, 2021.</p>\n<p>On June 16, 2021, trading of the existing shares of Molecular Partners on SIX will be halted. If trading of the ADS on the Nasdaq will commence at 4 p.m. CEST on June 16, 2021 or any time before, trading of the shares of Molecular Partners on SIX will reopen on the same day. If trading on the Nasdaq starts later, trading of the shares in Molecular Partners on SIX will reopen on June 17, 2021 only.</p>\n<p>The offering is expected to close on or about June 18, 2021, subject to customary closing conditions.</p>\n<p>J.P. Morgan, SVB Leerink and Cowen are acting as joint book-running managers for the proposed offering. RBC Capital Markets is acting as the bookrunner for the proposed offering. Kempen &amp; Co is acting as the lead manager for the proposed offering.</p>\n<p>A registration statement on Form F-1 relating to these securities became effective on June 15, 2021. The securities referred to in this release are to be offered only by means of a prospectus. Copies of the final prospectus relating to the offering may be obtained, when available, for free by visiting EDGAR on the SEC website at www.sec.gov. Alternatively, a written copy may be obtained for free from J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717, telephone: 1-866-803-9204; SVB Leerink LLC, Attention: Syndicate Department, One Federal Street, 37th Floor, Boston, MA 02110, by telephone at 1-800-808-7525, ext. 6105, or by e-mailing syndicate@svbleerink.com; Cowen and Company, LLC (c/o Broadridge Financial Services), 1155 Long Island Avenue, Edgewood, NY, 11717, Attn: Prospectus Department, by telephone at (833) 297-2926 or by email at PostSaleManualRequests@broadridge.com. The securities may not be sold, nor may offers to buy be accepted, prior to the time the registration statement becomes effective. In connection with the listing of the ordinary shares on the SIX, the registration statement on Form F-1 constitutes a foreign prospectus within the meaning of article 54 paras. 2 and 3 of the Swiss Financial Services Act of June 15, 2018 ('FinSA') and article 70 paras. 2-4 of the Swiss Financial Services Ordinance of November 6, 2019 ('FinSO'). The registration statement on Form F-1, including the preliminary prospectus, as well as the final prospectus, once available, will be deposited with the Prospectus Office of SIX Exchange Regulation. Further, the inclusion of the foreign prospectus in the prospectus list published by the Prospectus Office of SIX Exchange Regulation will be requested.</p>\n<p>This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. There is no intention or permission to publicly offer, solicit, sell or advertise, directly or indirectly, any securities of Molecular Partners in or into Switzerland within the meaning of FinSA.</p>\n<h4>About Molecular Partners AG</h4>\n<p>Molecular Partners AG is a clinical-stage biotech company developing DARPin® therapeutics, a new class of custom-built protein drugs designed to address challenges current modalities cannot. The Company has formed partnerships with leading pharmaceutical companies to advance DARPin® therapeutics in the areas of ophthalmology, oncology and infectious disease, and has compounds in various stages of clinical and preclinical development across multiple therapeutic areas.</p>","source":"yahoofinance","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Molecular Partners Announces Pricing of Initial Public Offering of American Depositary Shares in the United States</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMolecular Partners Announces Pricing of Initial Public Offering of American Depositary Shares in the United States\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-16 22:32 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/molecular-partners-announces-pricing-initial-020000537.html><strong>ACCESSWIRE</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>ZURICH-SCHLIEREN, SWITZERLAND / ACCESSWIRE / June 15, 2021 / Molecular Partners AG (SIX:MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin® ...</p>\n\n<a href=\"https://finance.yahoo.com/news/molecular-partners-announces-pricing-initial-020000537.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"UBCP":"联合合众银行","AFG":"美国金融集团有限公司","MOLN":"Molecular Partners AG","00626":"大众金融控股","00467":"联合能源集团"},"source_url":"https://finance.yahoo.com/news/molecular-partners-announces-pricing-initial-020000537.html","is_english":true,"share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","article_id":"2143879474","content_text":"ZURICH-SCHLIEREN, SWITZERLAND / ACCESSWIRE / June 15, 2021 / Molecular Partners AG (SIX:MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin® therapeutics, today announced the pricing of its initial public offering in the United States of 3,000,000 American Depositary Shares ('ADSs') at a public offering price of $21.25 per ADS, for total gross proceeds of approximately $63.8 million. All ADSs sold in the offering were offered by Molecular Partners. Each ADS will represent one Molecular Partners ordinary share. The new ordinary shares underlying the ADSs will be issued from Molecular Partners' authorized capital under exclusion of the existing shareholders' pre-emptive rights. In addition, Molecular Partners has granted the underwriters a 30-day option to purchase up to an additional 450,000 ADSs at the initial public offering price, less underwriting discounts and commissions.\nTrading of the ADSs is expected to commence on The Nasdaq Global Select Market on Wednesday, June 16, 2021 under the ticker symbol 'MOLN.' SIX Swiss Exchange ('SIX') approved the listing of the new ordinary shares underlying the ADSs as of June 17, 2021.\nOn June 16, 2021, trading of the existing shares of Molecular Partners on SIX will be halted. If trading of the ADS on the Nasdaq will commence at 4 p.m. CEST on June 16, 2021 or any time before, trading of the shares of Molecular Partners on SIX will reopen on the same day. If trading on the Nasdaq starts later, trading of the shares in Molecular Partners on SIX will reopen on June 17, 2021 only.\nThe offering is expected to close on or about June 18, 2021, subject to customary closing conditions.\nJ.P. Morgan, SVB Leerink and Cowen are acting as joint book-running managers for the proposed offering. RBC Capital Markets is acting as the bookrunner for the proposed offering. Kempen & Co is acting as the lead manager for the proposed offering.\nA registration statement on Form F-1 relating to these securities became effective on June 15, 2021. The securities referred to in this release are to be offered only by means of a prospectus. Copies of the final prospectus relating to the offering may be obtained, when available, for free by visiting EDGAR on the SEC website at www.sec.gov. Alternatively, a written copy may be obtained for free from J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717, telephone: 1-866-803-9204; SVB Leerink LLC, Attention: Syndicate Department, One Federal Street, 37th Floor, Boston, MA 02110, by telephone at 1-800-808-7525, ext. 6105, or by e-mailing syndicate@svbleerink.com; Cowen and Company, LLC (c/o Broadridge Financial Services), 1155 Long Island Avenue, Edgewood, NY, 11717, Attn: Prospectus Department, by telephone at (833) 297-2926 or by email at PostSaleManualRequests@broadridge.com. The securities may not be sold, nor may offers to buy be accepted, prior to the time the registration statement becomes effective. In connection with the listing of the ordinary shares on the SIX, the registration statement on Form F-1 constitutes a foreign prospectus within the meaning of article 54 paras. 2 and 3 of the Swiss Financial Services Act of June 15, 2018 ('FinSA') and article 70 paras. 2-4 of the Swiss Financial Services Ordinance of November 6, 2019 ('FinSO'). The registration statement on Form F-1, including the preliminary prospectus, as well as the final prospectus, once available, will be deposited with the Prospectus Office of SIX Exchange Regulation. Further, the inclusion of the foreign prospectus in the prospectus list published by the Prospectus Office of SIX Exchange Regulation will be requested.\nThis press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. There is no intention or permission to publicly offer, solicit, sell or advertise, directly or indirectly, any securities of Molecular Partners in or into Switzerland within the meaning of FinSA.\nAbout Molecular Partners AG\nMolecular Partners AG is a clinical-stage biotech company developing DARPin® therapeutics, a new class of custom-built protein drugs designed to address challenges current modalities cannot. The Company has formed partnerships with leading pharmaceutical companies to advance DARPin® therapeutics in the areas of ophthalmology, oncology and infectious disease, and has compounds in various stages of clinical and preclinical development across multiple therapeutic areas.","news_type":1},"isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":163025516,"gmtCreate":1623854162235,"gmtModify":1631886970139,"author":{"id":"3571619533976102","authorId":"3571619533976102","name":"TomCl","avatar":"https://static.tigerbbs.com/84c9633e30b56b9ef4c30ab8c67857b3","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3571619533976102","authorIdStr":"3571619533976102"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/AAL\">$AAL 20230120 27.0 CALL(AAL)$</a>nnice nieci","listText":"<a href=\"https://laohu8.com/S/AAL\">$AAL 20230120 27.0 CALL(AAL)$</a>nnice nieci","text":"$AAL 20230120 27.0 CALL(AAL)$nnice nieci","images":[{"img":"https://static.tigerbbs.com/e8776237d83ec54343b68473ba20ec70","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/163025516","isVote":1,"tweetType":1,"viewCount":410,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":187159347,"gmtCreate":1623747510689,"gmtModify":1631886970169,"author":{"id":"3571619533976102","authorId":"3571619533976102","name":"TomCl","avatar":"https://static.tigerbbs.com/84c9633e30b56b9ef4c30ab8c67857b3","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3571619533976102","authorIdStr":"3571619533976102"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/AAL\">$AAL 20230120 27.0 CALL(AAL)$</a>nnice nieci","listText":"<a href=\"https://laohu8.com/S/AAL\">$AAL 20230120 27.0 CALL(AAL)$</a>nnice nieci","text":"$AAL 20230120 27.0 CALL(AAL)$nnice nieci","images":[{"img":"https://static.tigerbbs.com/ffcf7ba8b7f8e31930df0f23dbeff0b4","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/187159347","isVote":1,"tweetType":1,"viewCount":187,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":197025498,"gmtCreate":1621412512814,"gmtModify":1631890890051,"author":{"id":"3571619533976102","authorId":"3571619533976102","name":"TomCl","avatar":"https://static.tigerbbs.com/84c9633e30b56b9ef4c30ab8c67857b3","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3571619533976102","authorIdStr":"3571619533976102"},"themes":[],"htmlText":"Nicely//<a href=\"https://laohu8.com/U/3571619533976102\">@TomCl</a>: Nicely","listText":"Nicely//<a href=\"https://laohu8.com/U/3571619533976102\">@TomCl</a>: Nicely","text":"Nicely//@TomCl: Nicely","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/197025498","repostId":"2134686276","repostType":4,"isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":190216986,"gmtCreate":1620622845345,"gmtModify":1631890890054,"author":{"id":"3571619533976102","authorId":"3571619533976102","name":"TomCl","avatar":"https://static.tigerbbs.com/84c9633e30b56b9ef4c30ab8c67857b3","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3571619533976102","authorIdStr":"3571619533976102"},"themes":[],"htmlText":"Nicely","listText":"Nicely","text":"Nicely","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":3,"repostSize":0,"link":"https://laohu8.com/post/190216986","repostId":"2134686276","repostType":4,"isVote":1,"tweetType":1,"viewCount":216,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":190218519,"gmtCreate":1620622832331,"gmtModify":1631890890062,"author":{"id":"3571619533976102","authorId":"3571619533976102","name":"TomCl","avatar":"https://static.tigerbbs.com/84c9633e30b56b9ef4c30ab8c67857b3","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3571619533976102","authorIdStr":"3571619533976102"},"themes":[],"htmlText":"Nicely","listText":"Nicely","text":"Nicely","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/190218519","repostId":"1171756066","repostType":4,"repost":{"id":"1171756066","kind":"news","pubTimestamp":1620614586,"share":"https://www.laohu8.com/m/news/1171756066?lang=&edition=full","pubTime":"2021-05-10 10:43","market":"us","language":"en","title":"5 Unbeatable Stocks to Buy for a Biden Bull Market","url":"https://stock-news.laohu8.com/highlight/detail?id=1171756066","media":"fool","summary":"When President Joe Biden took office on Jan. 20, 2021, he inherited one of the worst economic catastrophes in decades. The coronavirus disease 2019  pandemic wreaked havoc on the U.S. and global economy, and it briefly sent the U.S. stock market into a tailspin.However, a perfect storm could be brewing for equities under the Biden administration. The Federal Reserve has pledged to hold firm on historically low lending rates, while the White House is calling for trillions of dollars in additional","content":"<p>When President Joe Biden took office on Jan. 20, 2021, he inherited one of the worst economic catastrophes in decades. The coronavirus disease 2019 (COVID-19) pandemic wreaked havoc on the U.S. and global economy, and it briefly sent the U.S. stock market into a tailspin.</p>\n<p>However, a perfect storm could be brewing for equities under the Biden administration. The Federal Reserve has pledged to hold firm on historically low lending rates, while the White House is calling for trillions of dollars in additional spending. This abundant access to cheap capital is the perfect recipe for stocks to thrive in a rebounding economy.</p>\n<p>If a Biden bull market does take shape, the following five unbeatable stocks would be the perfect companies to own.</p>\n<p><b>Alphabet</b></p>\n<p>Few stocks are more synonymous with the word \"unbeatable\" than&nbsp;<b>Alphabet</b>(NASDAQ:GOOGL)(NASDAQ:GOOG), the parent company of internet search engine Google and streaming platform YouTube.</p>\n<p>Alphabet operates what might as well be a monopoly in internet search. According to GlobalStats, Google has consistently maintainedglobal search engine market share of 91% to 93%for at least the past two years. Its next-closest competitor,<b>Microsoft</b>'s Bing, hardly registered with a 2.29% share of the search engine market in April 2021. Being such a dominant force in search means advertisers will pay up for prime placement. It also suggests that the company's traffic acquisition costs should decline over time. As the U.S. and global economy improve, ad spending should really pick up.</p>\n<p>But Alphabetis about more than just internet search. Ad revenue generated from YouTube -- one of the three most-visited social sites on the planet -- jumped 49% in the first quarter to $6 billion. Meanwhile, revenue from cloud infrastructure segment Google Cloud rose 46% to $4 billion. These once small ancillary operations are now on track to contribute $40 billion in sales to Alphabet on an annual run-rate basis.</p>\n<p>Despite its $1.6 trillion price tag, Alphabet is still a bargain.</p>\n<p><b>AstraZeneca</b></p>\n<p>For two decades,pharmaceutical stock&nbsp;<b>AstraZeneca</b>(NASDAQ:AZN)was a largely forgettable drug developer that struggled with competition and the patent cliff. Today, it's reinvented itself into a bona fide growth stock with a bright future.</p>\n<p>The primary growth driver for AstraZenecais the company's oncology segment. In the first quarter alone, constant currency sales jumped 16% to $3.02 billion. The company's blockbuster trio of Tagrisso, Imfinzi, and Lynparza led the way with respective constant-currency sales growth of 13%, 17%, and 33%. Diabetes blockbuster drug Farxiga also deserves a mention with its 50% constant-currency sales growth in Q1 2021. The company's brand-name treatments are on fire, and it's led to sustainable double-digit topline growth.</p>\n<p>Equally exciting is AstraZeneca's pending acquisition of<b>Alexion Pharmaceuticals</b>(NASDAQ:ALXN). Alexion is a developer of ultra-rare therapeutics. Though it's risky developing treatments for such a small group of patients, success is usually met with no competition and little or no pushback from health insurers on high list prices.</p>\n<p>The best part about the Alexion deal is the companydeveloped a replacement for its top-selling drug, Soliris. The next-generation therapy, known as Ultomiris, is administered less frequently, which is a positive for patients. Eventually, Ultomiris will gobble up Soliris' sales and lock-up Alexion's/AstraZeneca's cash flow for a long time to come.</p>\n<p><b>Mastercard</b></p>\n<p>Another unbeatable stock that can deliver superior returns with Biden in the White House is payment facilitator<b>Mastercard</b>(NYSE:MA).</p>\n<p>Like mostfinancial stocks, Mastercard is cyclical. This means it struggles when the U.S. and global economy contract or enter a recession and it thrives when the economy is running on all cylinders. That's because it relies on merchant fees via payments to drive its top and bottom line. But the thing to understand about cyclical companies like Mastercard is that time is on their side. Whereas recessions often last for a few quarters, periods of expansion usually last many years. Considering how much money the Biden administration is attempting to pump into the U.S. economy, Mastercard should have a field day.</p>\n<p>Something else to consider is that Mastercardhas chosen not to be a lender. Although some of its peers do act as both processors and lenders (via credit cards), and are therefore able to double-dip during economic expansions, Mastercard's avoidance of lending is actually a smart move. When recessions inevitably strike and credit delinquencies rise, Mastercard doesn't have set aside cash. This is why it rebounds much quicker than its peers during the early stages of a recovery.</p>\n<p>The math here is simple: As the economy picks up steam, consumers and businesses are going to spend, spend, and spend some more. That's music to the ears of all Mastercard shareholders.</p>\n<p><b>Annaly Capital Management</b></p>\n<p>Don't worry, I haven't forgotten about you dividend income-seekers out there. If a Biden bull market takes shape, mortgage real estate investment trust (REIT)<b>Annaly Capital Management</b>(NYSE:NLY)could be a smart place to put your money to work.</p>\n<p>Without getting overly technical, mortgage REITs like Annaly borrow money at short-term lending rates and use it to purchase securities with higher long-term yields. In Annaly's case, we're primarily talking about mortgage-backed securities (MBS). The difference between the long-term yield received and the short-term borrowing rate is known as net interest margin (NIM). The wider the NIM, the more profitable Annaly is, and the bigger the dividend payout it can provide to shareholders. Right now, Annaly Capital isyielding a jaw-dropping 9.7%.</p>\n<p>What makes Annaly such a perfect stock to buy is thatwe're witnessing the yield curve steepen. When the U.S. economy is rebounding from a recession, it's normal for long-term yields to rise and for short-term yields to fall or flatten out. When this happens, Annaly usually experiences a widening of its NIM.</p>\n<p>Additionally, Annaly almost exclusively buys agency securities. This is a fancy way of saying that the MBSs it's purchasing are backed by the federal government in the event of a default. This protection is what allows the company to utilize leverage to its advantage, thereby pumping up its profits.</p>\n<p><b>Trupanion</b></p>\n<p>Lastly, companion animal health insurance company&nbsp;<b>Trupanion</b>(NASDAQ:TRUP)has all the look of an unbeatable stock to buy in a Biden bull market.</p>\n<p>The pet industry may not offer flashy growth prospects like cybersecurity or cannabis, but it's arguably themost consistent growth opportunity. It's been more than a quarter of a century since year-over-year U.S. pet expenditures declined. Further, the American Pet Products Association notes that the percentage of American household owning a pet has increased from 56% in 1988 to 67% by 2019-2020. If we've learned anything about pet owners, it's that they're willing to spend big bucks to ensure the well-being of their four-legged family members.</p>\n<p>Trupanion, which recently lifted the hood on its first-quarter operating results, isclosing in on 1 million total enrolled pets(943,854 at the end of Q1 2021). Amazingly, this only represents a little over 1% penetration of the U.S. market. In the U.K., about 1 in 4 pet owners purchases insurance for their cat or dog. If Trupanion can achieve a similar penetration rate, its addressable market would be more than $32 billion.</p>\n<p>This is a company that's spent two decades building up rapport with veterinarians and their staff at the clinical level. It's also the only major companion animal health insurance provider with software capable of handling payment to veterinarians at the time of checkout.</p>\n<p>The sky is the limit for Trupanion.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>5 Unbeatable Stocks to Buy for a Biden Bull Market</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n5 Unbeatable Stocks to Buy for a Biden Bull Market\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-05-10 10:43 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/05/09/5-unbeatable-stocks-to-buy-for-a-biden-bull-market/><strong>fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>When President Joe Biden took office on Jan. 20, 2021, he inherited one of the worst economic catastrophes in decades. The coronavirus disease 2019 (COVID-19) pandemic wreaked havoc on the U.S. and ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/05/09/5-unbeatable-stocks-to-buy-for-a-biden-bull-market/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"GOOGL":"谷歌A","TRUP":"Trupanion","NLY":"Annaly Capital Management","MA":"万事达","AZN":"阿斯利康"},"source_url":"https://www.fool.com/investing/2021/05/09/5-unbeatable-stocks-to-buy-for-a-biden-bull-market/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1171756066","content_text":"When President Joe Biden took office on Jan. 20, 2021, he inherited one of the worst economic catastrophes in decades. The coronavirus disease 2019 (COVID-19) pandemic wreaked havoc on the U.S. and global economy, and it briefly sent the U.S. stock market into a tailspin.\nHowever, a perfect storm could be brewing for equities under the Biden administration. The Federal Reserve has pledged to hold firm on historically low lending rates, while the White House is calling for trillions of dollars in additional spending. This abundant access to cheap capital is the perfect recipe for stocks to thrive in a rebounding economy.\nIf a Biden bull market does take shape, the following five unbeatable stocks would be the perfect companies to own.\nAlphabet\nFew stocks are more synonymous with the word \"unbeatable\" than Alphabet(NASDAQ:GOOGL)(NASDAQ:GOOG), the parent company of internet search engine Google and streaming platform YouTube.\nAlphabet operates what might as well be a monopoly in internet search. According to GlobalStats, Google has consistently maintainedglobal search engine market share of 91% to 93%for at least the past two years. Its next-closest competitor,Microsoft's Bing, hardly registered with a 2.29% share of the search engine market in April 2021. Being such a dominant force in search means advertisers will pay up for prime placement. It also suggests that the company's traffic acquisition costs should decline over time. As the U.S. and global economy improve, ad spending should really pick up.\nBut Alphabetis about more than just internet search. Ad revenue generated from YouTube -- one of the three most-visited social sites on the planet -- jumped 49% in the first quarter to $6 billion. Meanwhile, revenue from cloud infrastructure segment Google Cloud rose 46% to $4 billion. These once small ancillary operations are now on track to contribute $40 billion in sales to Alphabet on an annual run-rate basis.\nDespite its $1.6 trillion price tag, Alphabet is still a bargain.\nAstraZeneca\nFor two decades,pharmaceutical stock AstraZeneca(NASDAQ:AZN)was a largely forgettable drug developer that struggled with competition and the patent cliff. Today, it's reinvented itself into a bona fide growth stock with a bright future.\nThe primary growth driver for AstraZenecais the company's oncology segment. In the first quarter alone, constant currency sales jumped 16% to $3.02 billion. The company's blockbuster trio of Tagrisso, Imfinzi, and Lynparza led the way with respective constant-currency sales growth of 13%, 17%, and 33%. Diabetes blockbuster drug Farxiga also deserves a mention with its 50% constant-currency sales growth in Q1 2021. The company's brand-name treatments are on fire, and it's led to sustainable double-digit topline growth.\nEqually exciting is AstraZeneca's pending acquisition ofAlexion Pharmaceuticals(NASDAQ:ALXN). Alexion is a developer of ultra-rare therapeutics. Though it's risky developing treatments for such a small group of patients, success is usually met with no competition and little or no pushback from health insurers on high list prices.\nThe best part about the Alexion deal is the companydeveloped a replacement for its top-selling drug, Soliris. The next-generation therapy, known as Ultomiris, is administered less frequently, which is a positive for patients. Eventually, Ultomiris will gobble up Soliris' sales and lock-up Alexion's/AstraZeneca's cash flow for a long time to come.\nMastercard\nAnother unbeatable stock that can deliver superior returns with Biden in the White House is payment facilitatorMastercard(NYSE:MA).\nLike mostfinancial stocks, Mastercard is cyclical. This means it struggles when the U.S. and global economy contract or enter a recession and it thrives when the economy is running on all cylinders. That's because it relies on merchant fees via payments to drive its top and bottom line. But the thing to understand about cyclical companies like Mastercard is that time is on their side. Whereas recessions often last for a few quarters, periods of expansion usually last many years. Considering how much money the Biden administration is attempting to pump into the U.S. economy, Mastercard should have a field day.\nSomething else to consider is that Mastercardhas chosen not to be a lender. Although some of its peers do act as both processors and lenders (via credit cards), and are therefore able to double-dip during economic expansions, Mastercard's avoidance of lending is actually a smart move. When recessions inevitably strike and credit delinquencies rise, Mastercard doesn't have set aside cash. This is why it rebounds much quicker than its peers during the early stages of a recovery.\nThe math here is simple: As the economy picks up steam, consumers and businesses are going to spend, spend, and spend some more. That's music to the ears of all Mastercard shareholders.\nAnnaly Capital Management\nDon't worry, I haven't forgotten about you dividend income-seekers out there. If a Biden bull market takes shape, mortgage real estate investment trust (REIT)Annaly Capital Management(NYSE:NLY)could be a smart place to put your money to work.\nWithout getting overly technical, mortgage REITs like Annaly borrow money at short-term lending rates and use it to purchase securities with higher long-term yields. In Annaly's case, we're primarily talking about mortgage-backed securities (MBS). The difference between the long-term yield received and the short-term borrowing rate is known as net interest margin (NIM). The wider the NIM, the more profitable Annaly is, and the bigger the dividend payout it can provide to shareholders. Right now, Annaly Capital isyielding a jaw-dropping 9.7%.\nWhat makes Annaly such a perfect stock to buy is thatwe're witnessing the yield curve steepen. When the U.S. economy is rebounding from a recession, it's normal for long-term yields to rise and for short-term yields to fall or flatten out. When this happens, Annaly usually experiences a widening of its NIM.\nAdditionally, Annaly almost exclusively buys agency securities. This is a fancy way of saying that the MBSs it's purchasing are backed by the federal government in the event of a default. This protection is what allows the company to utilize leverage to its advantage, thereby pumping up its profits.\nTrupanion\nLastly, companion animal health insurance company Trupanion(NASDAQ:TRUP)has all the look of an unbeatable stock to buy in a Biden bull market.\nThe pet industry may not offer flashy growth prospects like cybersecurity or cannabis, but it's arguably themost consistent growth opportunity. It's been more than a quarter of a century since year-over-year U.S. pet expenditures declined. Further, the American Pet Products Association notes that the percentage of American household owning a pet has increased from 56% in 1988 to 67% by 2019-2020. If we've learned anything about pet owners, it's that they're willing to spend big bucks to ensure the well-being of their four-legged family members.\nTrupanion, which recently lifted the hood on its first-quarter operating results, isclosing in on 1 million total enrolled pets(943,854 at the end of Q1 2021). Amazingly, this only represents a little over 1% penetration of the U.S. market. In the U.K., about 1 in 4 pet owners purchases insurance for their cat or dog. If Trupanion can achieve a similar penetration rate, its addressable market would be more than $32 billion.\nThis is a company that's spent two decades building up rapport with veterinarians and their staff at the clinical level. It's also the only major companion animal health insurance provider with software capable of handling payment to veterinarians at the time of checkout.\nThe sky is the limit for Trupanion.","news_type":1},"isVote":1,"tweetType":1,"viewCount":171,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":190218621,"gmtCreate":1620622817563,"gmtModify":1631890890062,"author":{"id":"3571619533976102","authorId":"3571619533976102","name":"TomCl","avatar":"https://static.tigerbbs.com/84c9633e30b56b9ef4c30ab8c67857b3","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3571619533976102","authorIdStr":"3571619533976102"},"themes":[],"htmlText":"Nice","listText":"Nice","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/190218621","repostId":"1134875250","repostType":4,"repost":{"id":"1134875250","kind":"news","pubTimestamp":1620612288,"share":"https://www.laohu8.com/m/news/1134875250?lang=&edition=full","pubTime":"2021-05-10 10:04","market":"us","language":"en","title":"Cathie Wood Loads Up Another $28M Worth Of Shares In Alibaba Rival JD.Com","url":"https://stock-news.laohu8.com/highlight/detail?id=1134875250","media":"benzinga","summary":"Cathie Wood-led Ark Investment Management on Friday bought 366,879 shares, worth about $27.7 million, in JD.com Inc, a key rival to Alibaba Group Holding in the e-commerce space in China.Shares of JD.com closed 1.15% lower at $75.51 on Friday.Wood's firm has been piling up shares of Alibaba rivals, some of which now account for a better part of its holdings compared to the Jack Ma-led company, whose shareshave slumpedover 20% since October last year over troubles with the Chinese government.The ","content":"<p>Cathie Wood-led Ark Investment Management on Friday bought 366,879 shares, worth about $27.7 million, in&nbsp;<b>JD.com Inc</b>, a key rival to&nbsp;<b>Alibaba Group Holding</b>&nbsp;in the e-commerce space in China.</p><p>Shares of JD.com closed 1.15% lower at $75.51 on Friday.</p><p>Wood's firm has been piling up shares of Alibaba rivals, some of which now account for a better part of its holdings compared to the Jack Ma-led company, whose shareshave slumpedover 20% since October last year over troubles with the Chinese government.</p><p>The&nbsp;<b>ARK Innovation ETF</b>, which held about $112.5 million ahead of the trade on Friday, or 2.94% of the ETF weight, made the purchase. The stock ranks twelfth position among 47 stocks in ARKF.</p><p>The Beijing-headquartered JD.com runs one of the two massive B2C online retailers in China and is a major competitor to Alibaba-run Tmall.</p><p>Other Ark Buys On Friday:</p><ul><li><b>Coinbase Global Inc</b>COIN 2.7%</li><li><b>Veracyte Inc</b>VCYT 1.23%</li><li><b>908 Devices Inc</b>MASS 2.02%</li><li><b>Ionis Pharmaceuticals Inc</b>NASDAQINOS</li><li><b>Fate Therapeutics Inc</b>FATE 0.08%</li><li><b>CM Life Sciences II Inc</b>CMII 0.34%</li><li><b>CareDx Inc</b>CDNA 6.92%</li><li><b>Draftkings Inc</b>DKNG 6.69%</li><li><b>Unity Software Inc</b>U 1.23%</li><li><b>TuSimple Holdings</b>TSP 4.05%</li><li><b>Skillz Inc</b>SKLZ 2.01%</li><li><b>Kratos Defense &amp; Security Solutions Inc</b>KTOS 1.35%</li><li><b>One</b>AONE 0.2%</li><li><b>Iridium Communications Inc</b>IRDM 0.76%</li><li><b>Teradyne Inc</b>TER 1.77%</li><li><b>Twitter Inc</b>TWTR 0.07%</li><li><b>Nano Dimension Ltd</b>NNDM 2.93%</li><li><b>Okta Inc</b>OKTA 1.23%</li><li><b>Meituan</b>MPNGF 0.72%</li></ul><p>Ark Sells On Friday:</p><ul><li><b>Yeahka Ltd</b>YHEKF 9.94%</li><li><b>Silvergate Capital Corp</b>SI 4.33%</li><li><b>Takeda Pharmaceutical Co Ltd</b>TAK 1.5%</li><li><b>Syros Pharmaceuticals Inc</b>SYRS 5.97%</li><li><b>Roche Holding Ag</b>RHHBY 2.08%</li><li><b>Nanostring Technologies Inc</b>NSTG 3.03%</li><li><b>Lendingtree Inc</b>TREE 2.16%</li><li><b>Novartis Ag</b>NVS 0.68%</li><li><b>Pure Storage Inc</b>PSTG 2.03%</li><li><b>Baidu Inc</b>BIDU 0.41%</li><li><b>Nintendo Co Ltd</b>NTDOY 1.46%</li><li><b>Workhorse Group Inc</b>WKHS 0.31%</li><li><b>Virgin Galactic Holdings Inc (</b>NYSE: SPCE)</li><li><b>Crowdstrike Holdings Inc (</b>NASDAQ: CRWD)</li><li><b>Pinterest Inc</b>PINS 0.98%</li><li><b>Deere &amp; Co (</b>NYSE: DE)</li></ul>","source":"lsy1606299360108","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Cathie Wood Loads Up Another $28M Worth Of Shares In Alibaba Rival JD.Com</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCathie Wood Loads Up Another $28M Worth Of Shares In Alibaba Rival JD.Com\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-05-10 10:04 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.benzinga.com/etfs/sector-etfs/21/05/21027556/cathie-wood-loads-up-another-28m-worth-of-shares-in-alibaba-rival-jd-com><strong>benzinga</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Cathie Wood-led Ark Investment Management on Friday bought 366,879 shares, worth about $27.7 million, in JD.com Inc, a key rival to Alibaba Group Holding in the e-commerce space in China.Shares of ...</p>\n\n<a href=\"https://www.benzinga.com/etfs/sector-etfs/21/05/21027556/cathie-wood-loads-up-another-28m-worth-of-shares-in-alibaba-rival-jd-com\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BABA":"阿里巴巴","JD":"京东"},"source_url":"https://www.benzinga.com/etfs/sector-etfs/21/05/21027556/cathie-wood-loads-up-another-28m-worth-of-shares-in-alibaba-rival-jd-com","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1134875250","content_text":"Cathie Wood-led Ark Investment Management on Friday bought 366,879 shares, worth about $27.7 million, in JD.com Inc, a key rival to Alibaba Group Holding in the e-commerce space in China.Shares of JD.com closed 1.15% lower at $75.51 on Friday.Wood's firm has been piling up shares of Alibaba rivals, some of which now account for a better part of its holdings compared to the Jack Ma-led company, whose shareshave slumpedover 20% since October last year over troubles with the Chinese government.The ARK Innovation ETF, which held about $112.5 million ahead of the trade on Friday, or 2.94% of the ETF weight, made the purchase. The stock ranks twelfth position among 47 stocks in ARKF.The Beijing-headquartered JD.com runs one of the two massive B2C online retailers in China and is a major competitor to Alibaba-run Tmall.Other Ark Buys On Friday:Coinbase Global IncCOIN 2.7%Veracyte IncVCYT 1.23%908 Devices IncMASS 2.02%Ionis Pharmaceuticals IncNASDAQINOSFate Therapeutics IncFATE 0.08%CM Life Sciences II IncCMII 0.34%CareDx IncCDNA 6.92%Draftkings IncDKNG 6.69%Unity Software IncU 1.23%TuSimple HoldingsTSP 4.05%Skillz IncSKLZ 2.01%Kratos Defense & Security Solutions IncKTOS 1.35%OneAONE 0.2%Iridium Communications IncIRDM 0.76%Teradyne IncTER 1.77%Twitter IncTWTR 0.07%Nano Dimension LtdNNDM 2.93%Okta IncOKTA 1.23%MeituanMPNGF 0.72%Ark Sells On Friday:Yeahka LtdYHEKF 9.94%Silvergate Capital CorpSI 4.33%Takeda Pharmaceutical Co LtdTAK 1.5%Syros Pharmaceuticals IncSYRS 5.97%Roche Holding AgRHHBY 2.08%Nanostring Technologies IncNSTG 3.03%Lendingtree IncTREE 2.16%Novartis AgNVS 0.68%Pure Storage IncPSTG 2.03%Baidu IncBIDU 0.41%Nintendo Co LtdNTDOY 1.46%Workhorse Group IncWKHS 0.31%Virgin Galactic Holdings Inc (NYSE: SPCE)Crowdstrike Holdings Inc (NASDAQ: CRWD)Pinterest IncPINS 0.98%Deere & Co (NYSE: DE)","news_type":1},"isVote":1,"tweetType":1,"viewCount":203,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":105638330,"gmtCreate":1620296481120,"gmtModify":1631893073913,"author":{"id":"3571619533976102","authorId":"3571619533976102","name":"TomCl","avatar":"https://static.tigerbbs.com/84c9633e30b56b9ef4c30ab8c67857b3","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3571619533976102","authorIdStr":"3571619533976102"},"themes":[],"htmlText":"Nice nice","listText":"Nice nice","text":"Nice nice","images":[{"img":"https://static.tigerbbs.com/643561680a48d73f90dc683d5e373774","width":"1080","height":"2691"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/105638330","isVote":1,"tweetType":1,"viewCount":192,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":105631760,"gmtCreate":1620296458450,"gmtModify":1631893073917,"author":{"id":"3571619533976102","authorId":"3571619533976102","name":"TomCl","avatar":"https://static.tigerbbs.com/84c9633e30b56b9ef4c30ab8c67857b3","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3571619533976102","authorIdStr":"3571619533976102"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/SNDL\">$Sundial Growers Inc.(SNDL)$</a>nnice","listText":"<a href=\"https://laohu8.com/S/SNDL\">$Sundial Growers Inc.(SNDL)$</a>nnice","text":"$Sundial Growers Inc.(SNDL)$nnice","images":[{"img":"https://static.tigerbbs.com/bede97e5c63296fec9f742656d9a64a1","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/105631760","isVote":1,"tweetType":1,"viewCount":156,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":105631204,"gmtCreate":1620296431108,"gmtModify":1631893073919,"author":{"id":"3571619533976102","authorId":"3571619533976102","name":"TomCl","avatar":"https://static.tigerbbs.com/84c9633e30b56b9ef4c30ab8c67857b3","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3571619533976102","authorIdStr":"3571619533976102"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/SNDL\">$Sundial Growers Inc.(SNDL)$</a>nnice nieci","listText":"<a href=\"https://laohu8.com/S/SNDL\">$Sundial Growers Inc.(SNDL)$</a>nnice nieci","text":"$Sundial Growers Inc.(SNDL)$nnice nieci","images":[{"img":"https://static.tigerbbs.com/bede97e5c63296fec9f742656d9a64a1","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/105631204","isVote":1,"tweetType":1,"viewCount":118,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":102863555,"gmtCreate":1620194457977,"gmtModify":1631893073925,"author":{"id":"3571619533976102","authorId":"3571619533976102","name":"TomCl","avatar":"https://static.tigerbbs.com/84c9633e30b56b9ef4c30ab8c67857b3","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3571619533976102","authorIdStr":"3571619533976102"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/SNDL\">$Sundial Growers Inc.(SNDL)$</a>nive nice","listText":"<a href=\"https://laohu8.com/S/SNDL\">$Sundial Growers Inc.(SNDL)$</a>nive nice","text":"$Sundial Growers Inc.(SNDL)$nive nice","images":[{"img":"https://static.tigerbbs.com/0b2eb12693b8f6ecf14229e9a566de49","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/102863555","isVote":1,"tweetType":1,"viewCount":292,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":102869447,"gmtCreate":1620194334889,"gmtModify":1631893073925,"author":{"id":"3571619533976102","authorId":"3571619533976102","name":"TomCl","avatar":"https://static.tigerbbs.com/84c9633e30b56b9ef4c30ab8c67857b3","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3571619533976102","authorIdStr":"3571619533976102"},"themes":[],"htmlText":"Nice nice","listText":"Nice nice","text":"Nice nice","images":[{"img":"https://static.tigerbbs.com/f6ef167bf6935202904379daf636071a","width":"1080","height":"2691"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/102869447","isVote":1,"tweetType":1,"viewCount":133,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0}],"hots":[{"id":368156004,"gmtCreate":1614302382008,"gmtModify":1703476041201,"author":{"id":"3571619533976102","authorId":"3571619533976102","name":"TomCl","avatar":"https://static.tigerbbs.com/84c9633e30b56b9ef4c30ab8c67857b3","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3571619533976102","idStr":"3571619533976102"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/AMC\">$AMC Entertainment(AMC)$</a>haha","listText":"<a href=\"https://laohu8.com/S/AMC\">$AMC Entertainment(AMC)$</a>haha","text":"$AMC Entertainment(AMC)$haha","images":[{"img":"https://static.tigerbbs.com/d7b5a27826090295ac3ca5c3d6ebd698","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":3,"repostSize":0,"link":"https://laohu8.com/post/368156004","isVote":1,"tweetType":1,"viewCount":246,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":382950420,"gmtCreate":1613353383160,"gmtModify":1631885327525,"author":{"id":"3571619533976102","authorId":"3571619533976102","name":"TomCl","avatar":"https://static.tigerbbs.com/84c9633e30b56b9ef4c30ab8c67857b3","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3571619533976102","idStr":"3571619533976102"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/RIOT\">$Riot Blockchain, Inc.(RIOT)$</a>im doing surprisingly well","listText":"<a href=\"https://laohu8.com/S/RIOT\">$Riot Blockchain, Inc.(RIOT)$</a>im doing surprisingly well","text":"$Riot Blockchain, Inc.(RIOT)$im doing surprisingly well","images":[{"img":"https://static.tigerbbs.com/13b2efd3951a065e2862250421ce2c85","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/382950420","isVote":1,"tweetType":1,"viewCount":265,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":314678300,"gmtCreate":1612349123000,"gmtModify":1703760658543,"author":{"id":"3571619533976102","authorId":"3571619533976102","name":"TomCl","avatar":"https://static.tigerbbs.com/84c9633e30b56b9ef4c30ab8c67857b3","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3571619533976102","idStr":"3571619533976102"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/GME\">$GameStop(GME)$</a><a href=\"https://laohu8.com/S/SNDL\">$Sundial Growers Inc.(SNDL)$</a>GME + SNDL","listText":"<a href=\"https://laohu8.com/S/GME\">$GameStop(GME)$</a><a href=\"https://laohu8.com/S/SNDL\">$Sundial Growers Inc.(SNDL)$</a>GME + SNDL","text":"$GameStop(GME)$$Sundial Growers Inc.(SNDL)$GME + SNDL","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/314678300","isVote":1,"tweetType":1,"viewCount":727,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":161221259,"gmtCreate":1623929962671,"gmtModify":1631890890041,"author":{"id":"3571619533976102","authorId":"3571619533976102","name":"TomCl","avatar":"https://static.tigerbbs.com/84c9633e30b56b9ef4c30ab8c67857b3","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3571619533976102","idStr":"3571619533976102"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/SNDL\">$Sundial Growers Inc.(SNDL)$</a>nice nieci","listText":"<a href=\"https://laohu8.com/S/SNDL\">$Sundial Growers Inc.(SNDL)$</a>nice nieci","text":"$Sundial Growers Inc.(SNDL)$nice nieci","images":[{"img":"https://static.tigerbbs.com/fab74b2cd1a99b5693d5411f077730f3","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/161221259","isVote":1,"tweetType":1,"viewCount":469,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":190216986,"gmtCreate":1620622845345,"gmtModify":1631890890054,"author":{"id":"3571619533976102","authorId":"3571619533976102","name":"TomCl","avatar":"https://static.tigerbbs.com/84c9633e30b56b9ef4c30ab8c67857b3","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3571619533976102","idStr":"3571619533976102"},"themes":[],"htmlText":"Nicely","listText":"Nicely","text":"Nicely","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":3,"repostSize":0,"link":"https://laohu8.com/post/190216986","repostId":"2134686276","repostType":4,"isVote":1,"tweetType":1,"viewCount":216,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":105631760,"gmtCreate":1620296458450,"gmtModify":1631893073917,"author":{"id":"3571619533976102","authorId":"3571619533976102","name":"TomCl","avatar":"https://static.tigerbbs.com/84c9633e30b56b9ef4c30ab8c67857b3","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3571619533976102","idStr":"3571619533976102"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/SNDL\">$Sundial Growers Inc.(SNDL)$</a>nnice","listText":"<a href=\"https://laohu8.com/S/SNDL\">$Sundial Growers Inc.(SNDL)$</a>nnice","text":"$Sundial Growers Inc.(SNDL)$nnice","images":[{"img":"https://static.tigerbbs.com/bede97e5c63296fec9f742656d9a64a1","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/105631760","isVote":1,"tweetType":1,"viewCount":156,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":344073267,"gmtCreate":1618363341759,"gmtModify":1631888190396,"author":{"id":"3571619533976102","authorId":"3571619533976102","name":"TomCl","avatar":"https://static.tigerbbs.com/84c9633e30b56b9ef4c30ab8c67857b3","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3571619533976102","idStr":"3571619533976102"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/FNGU\">$Bank Of Montreal(FNGU)$</a>nnice","listText":"<a href=\"https://laohu8.com/S/FNGU\">$Bank Of Montreal(FNGU)$</a>nnice","text":"$Bank Of Montreal(FNGU)$nnice","images":[{"img":"https://static.tigerbbs.com/a52afd16493a963c981d2d66929df3c7","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/344073267","isVote":1,"tweetType":1,"viewCount":192,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":381174533,"gmtCreate":1612949907822,"gmtModify":1703767308875,"author":{"id":"3571619533976102","authorId":"3571619533976102","name":"TomCl","avatar":"https://static.tigerbbs.com/84c9633e30b56b9ef4c30ab8c67857b3","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3571619533976102","idStr":"3571619533976102"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/SNDL\">$Sundial Growers Inc.(SNDL)$</a>humble brag","listText":"<a href=\"https://laohu8.com/S/SNDL\">$Sundial Growers Inc.(SNDL)$</a>humble brag","text":"$Sundial Growers Inc.(SNDL)$humble brag","images":[{"img":"https://static.tigerbbs.com/a8588c3799b2ac0de1afffaae30d1d64","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/381174533","isVote":1,"tweetType":1,"viewCount":117,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":163050271,"gmtCreate":1623854239793,"gmtModify":1631890890041,"author":{"id":"3571619533976102","authorId":"3571619533976102","name":"TomCl","avatar":"https://static.tigerbbs.com/84c9633e30b56b9ef4c30ab8c67857b3","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3571619533976102","idStr":"3571619533976102"},"themes":[],"htmlText":"Good good","listText":"Good good","text":"Good good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/163050271","repostId":"2143879474","repostType":4,"repost":{"id":"2143879474","kind":"news","pubTimestamp":1623853920,"share":"https://www.laohu8.com/m/news/2143879474?lang=&edition=full","pubTime":"2021-06-16 22:32","market":"us","language":"en","title":"Molecular Partners Announces Pricing of Initial Public Offering of American Depositary Shares in the United States","url":"https://stock-news.laohu8.com/highlight/detail?id=2143879474","media":"ACCESSWIRE","summary":"ZURICH-SCHLIEREN, SWITZERLAND / ACCESSWIRE / June 15, 2021 / Molecular Partners AG (SIX:MOLN), a cli","content":"<p><b>ZURICH-SCHLIEREN, SWITZERLAND / ACCESSWIRE / June 15, 2021 / </b><a href=\"https://laohu8.com/S/MOLN\">Molecular Partners AG</a> (SIX:MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin® therapeutics, today announced the pricing of its initial public offering in the United States of 3,000,000 American Depositary Shares ('ADSs') at a public offering price of $21.25 per ADS, for total gross proceeds of approximately $63.8 million. All ADSs sold in the offering were offered by Molecular Partners. Each ADS will represent <a href=\"https://laohu8.com/S/AONE\">one</a> Molecular Partners ordinary share. The new ordinary shares underlying the ADSs will be issued from Molecular Partners' authorized capital under exclusion of the existing shareholders' pre-emptive rights. In addition, Molecular Partners has granted the underwriters a 30-day option to purchase up to an additional 450,000 ADSs at the initial public offering price, less underwriting discounts and commissions.</p>\n<p>Trading of the ADSs is expected to commence on The Nasdaq Global Select Market on Wednesday, June 16, 2021 under the ticker symbol 'MOLN.' SIX Swiss Exchange ('SIX') approved the listing of the new ordinary shares underlying the ADSs as of June 17, 2021.</p>\n<p>On June 16, 2021, trading of the existing shares of Molecular Partners on SIX will be halted. If trading of the ADS on the Nasdaq will commence at 4 p.m. CEST on June 16, 2021 or any time before, trading of the shares of Molecular Partners on SIX will reopen on the same day. If trading on the Nasdaq starts later, trading of the shares in Molecular Partners on SIX will reopen on June 17, 2021 only.</p>\n<p>The offering is expected to close on or about June 18, 2021, subject to customary closing conditions.</p>\n<p>J.P. Morgan, SVB Leerink and Cowen are acting as joint book-running managers for the proposed offering. RBC Capital Markets is acting as the bookrunner for the proposed offering. Kempen &amp; Co is acting as the lead manager for the proposed offering.</p>\n<p>A registration statement on Form F-1 relating to these securities became effective on June 15, 2021. The securities referred to in this release are to be offered only by means of a prospectus. Copies of the final prospectus relating to the offering may be obtained, when available, for free by visiting EDGAR on the SEC website at www.sec.gov. Alternatively, a written copy may be obtained for free from J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717, telephone: 1-866-803-9204; SVB Leerink LLC, Attention: Syndicate Department, One Federal Street, 37th Floor, Boston, MA 02110, by telephone at 1-800-808-7525, ext. 6105, or by e-mailing syndicate@svbleerink.com; Cowen and Company, LLC (c/o Broadridge Financial Services), 1155 Long Island Avenue, Edgewood, NY, 11717, Attn: Prospectus Department, by telephone at (833) 297-2926 or by email at PostSaleManualRequests@broadridge.com. The securities may not be sold, nor may offers to buy be accepted, prior to the time the registration statement becomes effective. In connection with the listing of the ordinary shares on the SIX, the registration statement on Form F-1 constitutes a foreign prospectus within the meaning of article 54 paras. 2 and 3 of the Swiss Financial Services Act of June 15, 2018 ('FinSA') and article 70 paras. 2-4 of the Swiss Financial Services Ordinance of November 6, 2019 ('FinSO'). The registration statement on Form F-1, including the preliminary prospectus, as well as the final prospectus, once available, will be deposited with the Prospectus Office of SIX Exchange Regulation. Further, the inclusion of the foreign prospectus in the prospectus list published by the Prospectus Office of SIX Exchange Regulation will be requested.</p>\n<p>This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. There is no intention or permission to publicly offer, solicit, sell or advertise, directly or indirectly, any securities of Molecular Partners in or into Switzerland within the meaning of FinSA.</p>\n<h4>About Molecular Partners AG</h4>\n<p>Molecular Partners AG is a clinical-stage biotech company developing DARPin® therapeutics, a new class of custom-built protein drugs designed to address challenges current modalities cannot. The Company has formed partnerships with leading pharmaceutical companies to advance DARPin® therapeutics in the areas of ophthalmology, oncology and infectious disease, and has compounds in various stages of clinical and preclinical development across multiple therapeutic areas.</p>","source":"yahoofinance","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Molecular Partners Announces Pricing of Initial Public Offering of American Depositary Shares in the United States</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMolecular Partners Announces Pricing of Initial Public Offering of American Depositary Shares in the United States\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-16 22:32 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/molecular-partners-announces-pricing-initial-020000537.html><strong>ACCESSWIRE</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>ZURICH-SCHLIEREN, SWITZERLAND / ACCESSWIRE / June 15, 2021 / Molecular Partners AG (SIX:MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin® ...</p>\n\n<a href=\"https://finance.yahoo.com/news/molecular-partners-announces-pricing-initial-020000537.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"UBCP":"联合合众银行","AFG":"美国金融集团有限公司","MOLN":"Molecular Partners AG","00626":"大众金融控股","00467":"联合能源集团"},"source_url":"https://finance.yahoo.com/news/molecular-partners-announces-pricing-initial-020000537.html","is_english":true,"share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","article_id":"2143879474","content_text":"ZURICH-SCHLIEREN, SWITZERLAND / ACCESSWIRE / June 15, 2021 / Molecular Partners AG (SIX:MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin® therapeutics, today announced the pricing of its initial public offering in the United States of 3,000,000 American Depositary Shares ('ADSs') at a public offering price of $21.25 per ADS, for total gross proceeds of approximately $63.8 million. All ADSs sold in the offering were offered by Molecular Partners. Each ADS will represent one Molecular Partners ordinary share. The new ordinary shares underlying the ADSs will be issued from Molecular Partners' authorized capital under exclusion of the existing shareholders' pre-emptive rights. In addition, Molecular Partners has granted the underwriters a 30-day option to purchase up to an additional 450,000 ADSs at the initial public offering price, less underwriting discounts and commissions.\nTrading of the ADSs is expected to commence on The Nasdaq Global Select Market on Wednesday, June 16, 2021 under the ticker symbol 'MOLN.' SIX Swiss Exchange ('SIX') approved the listing of the new ordinary shares underlying the ADSs as of June 17, 2021.\nOn June 16, 2021, trading of the existing shares of Molecular Partners on SIX will be halted. If trading of the ADS on the Nasdaq will commence at 4 p.m. CEST on June 16, 2021 or any time before, trading of the shares of Molecular Partners on SIX will reopen on the same day. If trading on the Nasdaq starts later, trading of the shares in Molecular Partners on SIX will reopen on June 17, 2021 only.\nThe offering is expected to close on or about June 18, 2021, subject to customary closing conditions.\nJ.P. Morgan, SVB Leerink and Cowen are acting as joint book-running managers for the proposed offering. RBC Capital Markets is acting as the bookrunner for the proposed offering. Kempen & Co is acting as the lead manager for the proposed offering.\nA registration statement on Form F-1 relating to these securities became effective on June 15, 2021. The securities referred to in this release are to be offered only by means of a prospectus. Copies of the final prospectus relating to the offering may be obtained, when available, for free by visiting EDGAR on the SEC website at www.sec.gov. Alternatively, a written copy may be obtained for free from J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717, telephone: 1-866-803-9204; SVB Leerink LLC, Attention: Syndicate Department, One Federal Street, 37th Floor, Boston, MA 02110, by telephone at 1-800-808-7525, ext. 6105, or by e-mailing syndicate@svbleerink.com; Cowen and Company, LLC (c/o Broadridge Financial Services), 1155 Long Island Avenue, Edgewood, NY, 11717, Attn: Prospectus Department, by telephone at (833) 297-2926 or by email at PostSaleManualRequests@broadridge.com. The securities may not be sold, nor may offers to buy be accepted, prior to the time the registration statement becomes effective. In connection with the listing of the ordinary shares on the SIX, the registration statement on Form F-1 constitutes a foreign prospectus within the meaning of article 54 paras. 2 and 3 of the Swiss Financial Services Act of June 15, 2018 ('FinSA') and article 70 paras. 2-4 of the Swiss Financial Services Ordinance of November 6, 2019 ('FinSO'). The registration statement on Form F-1, including the preliminary prospectus, as well as the final prospectus, once available, will be deposited with the Prospectus Office of SIX Exchange Regulation. Further, the inclusion of the foreign prospectus in the prospectus list published by the Prospectus Office of SIX Exchange Regulation will be requested.\nThis press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. There is no intention or permission to publicly offer, solicit, sell or advertise, directly or indirectly, any securities of Molecular Partners in or into Switzerland within the meaning of FinSA.\nAbout Molecular Partners AG\nMolecular Partners AG is a clinical-stage biotech company developing DARPin® therapeutics, a new class of custom-built protein drugs designed to address challenges current modalities cannot. The Company has formed partnerships with leading pharmaceutical companies to advance DARPin® therapeutics in the areas of ophthalmology, oncology and infectious disease, and has compounds in various stages of clinical and preclinical development across multiple therapeutic areas.","news_type":1},"isVote":1,"tweetType":1,"viewCount":247,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":163027475,"gmtCreate":1623854226797,"gmtModify":1631890890044,"author":{"id":"3571619533976102","authorId":"3571619533976102","name":"TomCl","avatar":"https://static.tigerbbs.com/84c9633e30b56b9ef4c30ab8c67857b3","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3571619533976102","idStr":"3571619533976102"},"themes":[],"htmlText":"Good good","listText":"Good good","text":"Good good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/163027475","repostId":"2143879474","repostType":4,"repost":{"id":"2143879474","kind":"news","pubTimestamp":1623853920,"share":"https://www.laohu8.com/m/news/2143879474?lang=&edition=full","pubTime":"2021-06-16 22:32","market":"us","language":"en","title":"Molecular Partners Announces Pricing of Initial Public Offering of American Depositary Shares in the United States","url":"https://stock-news.laohu8.com/highlight/detail?id=2143879474","media":"ACCESSWIRE","summary":"ZURICH-SCHLIEREN, SWITZERLAND / ACCESSWIRE / June 15, 2021 / Molecular Partners AG (SIX:MOLN), a cli","content":"<p><b>ZURICH-SCHLIEREN, SWITZERLAND / ACCESSWIRE / June 15, 2021 / </b><a href=\"https://laohu8.com/S/MOLN\">Molecular Partners AG</a> (SIX:MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin® therapeutics, today announced the pricing of its initial public offering in the United States of 3,000,000 American Depositary Shares ('ADSs') at a public offering price of $21.25 per ADS, for total gross proceeds of approximately $63.8 million. All ADSs sold in the offering were offered by Molecular Partners. Each ADS will represent <a href=\"https://laohu8.com/S/AONE\">one</a> Molecular Partners ordinary share. The new ordinary shares underlying the ADSs will be issued from Molecular Partners' authorized capital under exclusion of the existing shareholders' pre-emptive rights. In addition, Molecular Partners has granted the underwriters a 30-day option to purchase up to an additional 450,000 ADSs at the initial public offering price, less underwriting discounts and commissions.</p>\n<p>Trading of the ADSs is expected to commence on The Nasdaq Global Select Market on Wednesday, June 16, 2021 under the ticker symbol 'MOLN.' SIX Swiss Exchange ('SIX') approved the listing of the new ordinary shares underlying the ADSs as of June 17, 2021.</p>\n<p>On June 16, 2021, trading of the existing shares of Molecular Partners on SIX will be halted. If trading of the ADS on the Nasdaq will commence at 4 p.m. CEST on June 16, 2021 or any time before, trading of the shares of Molecular Partners on SIX will reopen on the same day. If trading on the Nasdaq starts later, trading of the shares in Molecular Partners on SIX will reopen on June 17, 2021 only.</p>\n<p>The offering is expected to close on or about June 18, 2021, subject to customary closing conditions.</p>\n<p>J.P. Morgan, SVB Leerink and Cowen are acting as joint book-running managers for the proposed offering. RBC Capital Markets is acting as the bookrunner for the proposed offering. Kempen &amp; Co is acting as the lead manager for the proposed offering.</p>\n<p>A registration statement on Form F-1 relating to these securities became effective on June 15, 2021. The securities referred to in this release are to be offered only by means of a prospectus. Copies of the final prospectus relating to the offering may be obtained, when available, for free by visiting EDGAR on the SEC website at www.sec.gov. Alternatively, a written copy may be obtained for free from J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717, telephone: 1-866-803-9204; SVB Leerink LLC, Attention: Syndicate Department, One Federal Street, 37th Floor, Boston, MA 02110, by telephone at 1-800-808-7525, ext. 6105, or by e-mailing syndicate@svbleerink.com; Cowen and Company, LLC (c/o Broadridge Financial Services), 1155 Long Island Avenue, Edgewood, NY, 11717, Attn: Prospectus Department, by telephone at (833) 297-2926 or by email at PostSaleManualRequests@broadridge.com. The securities may not be sold, nor may offers to buy be accepted, prior to the time the registration statement becomes effective. In connection with the listing of the ordinary shares on the SIX, the registration statement on Form F-1 constitutes a foreign prospectus within the meaning of article 54 paras. 2 and 3 of the Swiss Financial Services Act of June 15, 2018 ('FinSA') and article 70 paras. 2-4 of the Swiss Financial Services Ordinance of November 6, 2019 ('FinSO'). The registration statement on Form F-1, including the preliminary prospectus, as well as the final prospectus, once available, will be deposited with the Prospectus Office of SIX Exchange Regulation. Further, the inclusion of the foreign prospectus in the prospectus list published by the Prospectus Office of SIX Exchange Regulation will be requested.</p>\n<p>This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. There is no intention or permission to publicly offer, solicit, sell or advertise, directly or indirectly, any securities of Molecular Partners in or into Switzerland within the meaning of FinSA.</p>\n<h4>About Molecular Partners AG</h4>\n<p>Molecular Partners AG is a clinical-stage biotech company developing DARPin® therapeutics, a new class of custom-built protein drugs designed to address challenges current modalities cannot. The Company has formed partnerships with leading pharmaceutical companies to advance DARPin® therapeutics in the areas of ophthalmology, oncology and infectious disease, and has compounds in various stages of clinical and preclinical development across multiple therapeutic areas.</p>","source":"yahoofinance","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Molecular Partners Announces Pricing of Initial Public Offering of American Depositary Shares in the United States</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMolecular Partners Announces Pricing of Initial Public Offering of American Depositary Shares in the United States\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-16 22:32 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/molecular-partners-announces-pricing-initial-020000537.html><strong>ACCESSWIRE</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>ZURICH-SCHLIEREN, SWITZERLAND / ACCESSWIRE / June 15, 2021 / Molecular Partners AG (SIX:MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin® ...</p>\n\n<a href=\"https://finance.yahoo.com/news/molecular-partners-announces-pricing-initial-020000537.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"UBCP":"联合合众银行","AFG":"美国金融集团有限公司","MOLN":"Molecular Partners AG","00626":"大众金融控股","00467":"联合能源集团"},"source_url":"https://finance.yahoo.com/news/molecular-partners-announces-pricing-initial-020000537.html","is_english":true,"share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","article_id":"2143879474","content_text":"ZURICH-SCHLIEREN, SWITZERLAND / ACCESSWIRE / June 15, 2021 / Molecular Partners AG (SIX:MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin® therapeutics, today announced the pricing of its initial public offering in the United States of 3,000,000 American Depositary Shares ('ADSs') at a public offering price of $21.25 per ADS, for total gross proceeds of approximately $63.8 million. All ADSs sold in the offering were offered by Molecular Partners. Each ADS will represent one Molecular Partners ordinary share. The new ordinary shares underlying the ADSs will be issued from Molecular Partners' authorized capital under exclusion of the existing shareholders' pre-emptive rights. In addition, Molecular Partners has granted the underwriters a 30-day option to purchase up to an additional 450,000 ADSs at the initial public offering price, less underwriting discounts and commissions.\nTrading of the ADSs is expected to commence on The Nasdaq Global Select Market on Wednesday, June 16, 2021 under the ticker symbol 'MOLN.' SIX Swiss Exchange ('SIX') approved the listing of the new ordinary shares underlying the ADSs as of June 17, 2021.\nOn June 16, 2021, trading of the existing shares of Molecular Partners on SIX will be halted. If trading of the ADS on the Nasdaq will commence at 4 p.m. CEST on June 16, 2021 or any time before, trading of the shares of Molecular Partners on SIX will reopen on the same day. If trading on the Nasdaq starts later, trading of the shares in Molecular Partners on SIX will reopen on June 17, 2021 only.\nThe offering is expected to close on or about June 18, 2021, subject to customary closing conditions.\nJ.P. Morgan, SVB Leerink and Cowen are acting as joint book-running managers for the proposed offering. RBC Capital Markets is acting as the bookrunner for the proposed offering. Kempen & Co is acting as the lead manager for the proposed offering.\nA registration statement on Form F-1 relating to these securities became effective on June 15, 2021. The securities referred to in this release are to be offered only by means of a prospectus. Copies of the final prospectus relating to the offering may be obtained, when available, for free by visiting EDGAR on the SEC website at www.sec.gov. Alternatively, a written copy may be obtained for free from J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717, telephone: 1-866-803-9204; SVB Leerink LLC, Attention: Syndicate Department, One Federal Street, 37th Floor, Boston, MA 02110, by telephone at 1-800-808-7525, ext. 6105, or by e-mailing syndicate@svbleerink.com; Cowen and Company, LLC (c/o Broadridge Financial Services), 1155 Long Island Avenue, Edgewood, NY, 11717, Attn: Prospectus Department, by telephone at (833) 297-2926 or by email at PostSaleManualRequests@broadridge.com. The securities may not be sold, nor may offers to buy be accepted, prior to the time the registration statement becomes effective. In connection with the listing of the ordinary shares on the SIX, the registration statement on Form F-1 constitutes a foreign prospectus within the meaning of article 54 paras. 2 and 3 of the Swiss Financial Services Act of June 15, 2018 ('FinSA') and article 70 paras. 2-4 of the Swiss Financial Services Ordinance of November 6, 2019 ('FinSO'). The registration statement on Form F-1, including the preliminary prospectus, as well as the final prospectus, once available, will be deposited with the Prospectus Office of SIX Exchange Regulation. Further, the inclusion of the foreign prospectus in the prospectus list published by the Prospectus Office of SIX Exchange Regulation will be requested.\nThis press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. There is no intention or permission to publicly offer, solicit, sell or advertise, directly or indirectly, any securities of Molecular Partners in or into Switzerland within the meaning of FinSA.\nAbout Molecular Partners AG\nMolecular Partners AG is a clinical-stage biotech company developing DARPin® therapeutics, a new class of custom-built protein drugs designed to address challenges current modalities cannot. The Company has formed partnerships with leading pharmaceutical companies to advance DARPin® therapeutics in the areas of ophthalmology, oncology and infectious disease, and has compounds in various stages of clinical and preclinical development across multiple therapeutic areas.","news_type":1},"isVote":1,"tweetType":1,"viewCount":292,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":190218519,"gmtCreate":1620622832331,"gmtModify":1631890890062,"author":{"id":"3571619533976102","authorId":"3571619533976102","name":"TomCl","avatar":"https://static.tigerbbs.com/84c9633e30b56b9ef4c30ab8c67857b3","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3571619533976102","idStr":"3571619533976102"},"themes":[],"htmlText":"Nicely","listText":"Nicely","text":"Nicely","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/190218519","repostId":"1171756066","repostType":4,"repost":{"id":"1171756066","kind":"news","pubTimestamp":1620614586,"share":"https://www.laohu8.com/m/news/1171756066?lang=&edition=full","pubTime":"2021-05-10 10:43","market":"us","language":"en","title":"5 Unbeatable Stocks to Buy for a Biden Bull Market","url":"https://stock-news.laohu8.com/highlight/detail?id=1171756066","media":"fool","summary":"When President Joe Biden took office on Jan. 20, 2021, he inherited one of the worst economic catastrophes in decades. The coronavirus disease 2019  pandemic wreaked havoc on the U.S. and global economy, and it briefly sent the U.S. stock market into a tailspin.However, a perfect storm could be brewing for equities under the Biden administration. The Federal Reserve has pledged to hold firm on historically low lending rates, while the White House is calling for trillions of dollars in additional","content":"<p>When President Joe Biden took office on Jan. 20, 2021, he inherited one of the worst economic catastrophes in decades. The coronavirus disease 2019 (COVID-19) pandemic wreaked havoc on the U.S. and global economy, and it briefly sent the U.S. stock market into a tailspin.</p>\n<p>However, a perfect storm could be brewing for equities under the Biden administration. The Federal Reserve has pledged to hold firm on historically low lending rates, while the White House is calling for trillions of dollars in additional spending. This abundant access to cheap capital is the perfect recipe for stocks to thrive in a rebounding economy.</p>\n<p>If a Biden bull market does take shape, the following five unbeatable stocks would be the perfect companies to own.</p>\n<p><b>Alphabet</b></p>\n<p>Few stocks are more synonymous with the word \"unbeatable\" than&nbsp;<b>Alphabet</b>(NASDAQ:GOOGL)(NASDAQ:GOOG), the parent company of internet search engine Google and streaming platform YouTube.</p>\n<p>Alphabet operates what might as well be a monopoly in internet search. According to GlobalStats, Google has consistently maintainedglobal search engine market share of 91% to 93%for at least the past two years. Its next-closest competitor,<b>Microsoft</b>'s Bing, hardly registered with a 2.29% share of the search engine market in April 2021. Being such a dominant force in search means advertisers will pay up for prime placement. It also suggests that the company's traffic acquisition costs should decline over time. As the U.S. and global economy improve, ad spending should really pick up.</p>\n<p>But Alphabetis about more than just internet search. Ad revenue generated from YouTube -- one of the three most-visited social sites on the planet -- jumped 49% in the first quarter to $6 billion. Meanwhile, revenue from cloud infrastructure segment Google Cloud rose 46% to $4 billion. These once small ancillary operations are now on track to contribute $40 billion in sales to Alphabet on an annual run-rate basis.</p>\n<p>Despite its $1.6 trillion price tag, Alphabet is still a bargain.</p>\n<p><b>AstraZeneca</b></p>\n<p>For two decades,pharmaceutical stock&nbsp;<b>AstraZeneca</b>(NASDAQ:AZN)was a largely forgettable drug developer that struggled with competition and the patent cliff. Today, it's reinvented itself into a bona fide growth stock with a bright future.</p>\n<p>The primary growth driver for AstraZenecais the company's oncology segment. In the first quarter alone, constant currency sales jumped 16% to $3.02 billion. The company's blockbuster trio of Tagrisso, Imfinzi, and Lynparza led the way with respective constant-currency sales growth of 13%, 17%, and 33%. Diabetes blockbuster drug Farxiga also deserves a mention with its 50% constant-currency sales growth in Q1 2021. The company's brand-name treatments are on fire, and it's led to sustainable double-digit topline growth.</p>\n<p>Equally exciting is AstraZeneca's pending acquisition of<b>Alexion Pharmaceuticals</b>(NASDAQ:ALXN). Alexion is a developer of ultra-rare therapeutics. Though it's risky developing treatments for such a small group of patients, success is usually met with no competition and little or no pushback from health insurers on high list prices.</p>\n<p>The best part about the Alexion deal is the companydeveloped a replacement for its top-selling drug, Soliris. The next-generation therapy, known as Ultomiris, is administered less frequently, which is a positive for patients. Eventually, Ultomiris will gobble up Soliris' sales and lock-up Alexion's/AstraZeneca's cash flow for a long time to come.</p>\n<p><b>Mastercard</b></p>\n<p>Another unbeatable stock that can deliver superior returns with Biden in the White House is payment facilitator<b>Mastercard</b>(NYSE:MA).</p>\n<p>Like mostfinancial stocks, Mastercard is cyclical. This means it struggles when the U.S. and global economy contract or enter a recession and it thrives when the economy is running on all cylinders. That's because it relies on merchant fees via payments to drive its top and bottom line. But the thing to understand about cyclical companies like Mastercard is that time is on their side. Whereas recessions often last for a few quarters, periods of expansion usually last many years. Considering how much money the Biden administration is attempting to pump into the U.S. economy, Mastercard should have a field day.</p>\n<p>Something else to consider is that Mastercardhas chosen not to be a lender. Although some of its peers do act as both processors and lenders (via credit cards), and are therefore able to double-dip during economic expansions, Mastercard's avoidance of lending is actually a smart move. When recessions inevitably strike and credit delinquencies rise, Mastercard doesn't have set aside cash. This is why it rebounds much quicker than its peers during the early stages of a recovery.</p>\n<p>The math here is simple: As the economy picks up steam, consumers and businesses are going to spend, spend, and spend some more. That's music to the ears of all Mastercard shareholders.</p>\n<p><b>Annaly Capital Management</b></p>\n<p>Don't worry, I haven't forgotten about you dividend income-seekers out there. If a Biden bull market takes shape, mortgage real estate investment trust (REIT)<b>Annaly Capital Management</b>(NYSE:NLY)could be a smart place to put your money to work.</p>\n<p>Without getting overly technical, mortgage REITs like Annaly borrow money at short-term lending rates and use it to purchase securities with higher long-term yields. In Annaly's case, we're primarily talking about mortgage-backed securities (MBS). The difference between the long-term yield received and the short-term borrowing rate is known as net interest margin (NIM). The wider the NIM, the more profitable Annaly is, and the bigger the dividend payout it can provide to shareholders. Right now, Annaly Capital isyielding a jaw-dropping 9.7%.</p>\n<p>What makes Annaly such a perfect stock to buy is thatwe're witnessing the yield curve steepen. When the U.S. economy is rebounding from a recession, it's normal for long-term yields to rise and for short-term yields to fall or flatten out. When this happens, Annaly usually experiences a widening of its NIM.</p>\n<p>Additionally, Annaly almost exclusively buys agency securities. This is a fancy way of saying that the MBSs it's purchasing are backed by the federal government in the event of a default. This protection is what allows the company to utilize leverage to its advantage, thereby pumping up its profits.</p>\n<p><b>Trupanion</b></p>\n<p>Lastly, companion animal health insurance company&nbsp;<b>Trupanion</b>(NASDAQ:TRUP)has all the look of an unbeatable stock to buy in a Biden bull market.</p>\n<p>The pet industry may not offer flashy growth prospects like cybersecurity or cannabis, but it's arguably themost consistent growth opportunity. It's been more than a quarter of a century since year-over-year U.S. pet expenditures declined. Further, the American Pet Products Association notes that the percentage of American household owning a pet has increased from 56% in 1988 to 67% by 2019-2020. If we've learned anything about pet owners, it's that they're willing to spend big bucks to ensure the well-being of their four-legged family members.</p>\n<p>Trupanion, which recently lifted the hood on its first-quarter operating results, isclosing in on 1 million total enrolled pets(943,854 at the end of Q1 2021). Amazingly, this only represents a little over 1% penetration of the U.S. market. In the U.K., about 1 in 4 pet owners purchases insurance for their cat or dog. If Trupanion can achieve a similar penetration rate, its addressable market would be more than $32 billion.</p>\n<p>This is a company that's spent two decades building up rapport with veterinarians and their staff at the clinical level. It's also the only major companion animal health insurance provider with software capable of handling payment to veterinarians at the time of checkout.</p>\n<p>The sky is the limit for Trupanion.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>5 Unbeatable Stocks to Buy for a Biden Bull Market</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n5 Unbeatable Stocks to Buy for a Biden Bull Market\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-05-10 10:43 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/05/09/5-unbeatable-stocks-to-buy-for-a-biden-bull-market/><strong>fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>When President Joe Biden took office on Jan. 20, 2021, he inherited one of the worst economic catastrophes in decades. The coronavirus disease 2019 (COVID-19) pandemic wreaked havoc on the U.S. and ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/05/09/5-unbeatable-stocks-to-buy-for-a-biden-bull-market/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"GOOGL":"谷歌A","TRUP":"Trupanion","NLY":"Annaly Capital Management","MA":"万事达","AZN":"阿斯利康"},"source_url":"https://www.fool.com/investing/2021/05/09/5-unbeatable-stocks-to-buy-for-a-biden-bull-market/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1171756066","content_text":"When President Joe Biden took office on Jan. 20, 2021, he inherited one of the worst economic catastrophes in decades. The coronavirus disease 2019 (COVID-19) pandemic wreaked havoc on the U.S. and global economy, and it briefly sent the U.S. stock market into a tailspin.\nHowever, a perfect storm could be brewing for equities under the Biden administration. The Federal Reserve has pledged to hold firm on historically low lending rates, while the White House is calling for trillions of dollars in additional spending. This abundant access to cheap capital is the perfect recipe for stocks to thrive in a rebounding economy.\nIf a Biden bull market does take shape, the following five unbeatable stocks would be the perfect companies to own.\nAlphabet\nFew stocks are more synonymous with the word \"unbeatable\" than Alphabet(NASDAQ:GOOGL)(NASDAQ:GOOG), the parent company of internet search engine Google and streaming platform YouTube.\nAlphabet operates what might as well be a monopoly in internet search. According to GlobalStats, Google has consistently maintainedglobal search engine market share of 91% to 93%for at least the past two years. Its next-closest competitor,Microsoft's Bing, hardly registered with a 2.29% share of the search engine market in April 2021. Being such a dominant force in search means advertisers will pay up for prime placement. It also suggests that the company's traffic acquisition costs should decline over time. As the U.S. and global economy improve, ad spending should really pick up.\nBut Alphabetis about more than just internet search. Ad revenue generated from YouTube -- one of the three most-visited social sites on the planet -- jumped 49% in the first quarter to $6 billion. Meanwhile, revenue from cloud infrastructure segment Google Cloud rose 46% to $4 billion. These once small ancillary operations are now on track to contribute $40 billion in sales to Alphabet on an annual run-rate basis.\nDespite its $1.6 trillion price tag, Alphabet is still a bargain.\nAstraZeneca\nFor two decades,pharmaceutical stock AstraZeneca(NASDAQ:AZN)was a largely forgettable drug developer that struggled with competition and the patent cliff. Today, it's reinvented itself into a bona fide growth stock with a bright future.\nThe primary growth driver for AstraZenecais the company's oncology segment. In the first quarter alone, constant currency sales jumped 16% to $3.02 billion. The company's blockbuster trio of Tagrisso, Imfinzi, and Lynparza led the way with respective constant-currency sales growth of 13%, 17%, and 33%. Diabetes blockbuster drug Farxiga also deserves a mention with its 50% constant-currency sales growth in Q1 2021. The company's brand-name treatments are on fire, and it's led to sustainable double-digit topline growth.\nEqually exciting is AstraZeneca's pending acquisition ofAlexion Pharmaceuticals(NASDAQ:ALXN). Alexion is a developer of ultra-rare therapeutics. Though it's risky developing treatments for such a small group of patients, success is usually met with no competition and little or no pushback from health insurers on high list prices.\nThe best part about the Alexion deal is the companydeveloped a replacement for its top-selling drug, Soliris. The next-generation therapy, known as Ultomiris, is administered less frequently, which is a positive for patients. Eventually, Ultomiris will gobble up Soliris' sales and lock-up Alexion's/AstraZeneca's cash flow for a long time to come.\nMastercard\nAnother unbeatable stock that can deliver superior returns with Biden in the White House is payment facilitatorMastercard(NYSE:MA).\nLike mostfinancial stocks, Mastercard is cyclical. This means it struggles when the U.S. and global economy contract or enter a recession and it thrives when the economy is running on all cylinders. That's because it relies on merchant fees via payments to drive its top and bottom line. But the thing to understand about cyclical companies like Mastercard is that time is on their side. Whereas recessions often last for a few quarters, periods of expansion usually last many years. Considering how much money the Biden administration is attempting to pump into the U.S. economy, Mastercard should have a field day.\nSomething else to consider is that Mastercardhas chosen not to be a lender. Although some of its peers do act as both processors and lenders (via credit cards), and are therefore able to double-dip during economic expansions, Mastercard's avoidance of lending is actually a smart move. When recessions inevitably strike and credit delinquencies rise, Mastercard doesn't have set aside cash. This is why it rebounds much quicker than its peers during the early stages of a recovery.\nThe math here is simple: As the economy picks up steam, consumers and businesses are going to spend, spend, and spend some more. That's music to the ears of all Mastercard shareholders.\nAnnaly Capital Management\nDon't worry, I haven't forgotten about you dividend income-seekers out there. If a Biden bull market takes shape, mortgage real estate investment trust (REIT)Annaly Capital Management(NYSE:NLY)could be a smart place to put your money to work.\nWithout getting overly technical, mortgage REITs like Annaly borrow money at short-term lending rates and use it to purchase securities with higher long-term yields. In Annaly's case, we're primarily talking about mortgage-backed securities (MBS). The difference between the long-term yield received and the short-term borrowing rate is known as net interest margin (NIM). The wider the NIM, the more profitable Annaly is, and the bigger the dividend payout it can provide to shareholders. Right now, Annaly Capital isyielding a jaw-dropping 9.7%.\nWhat makes Annaly such a perfect stock to buy is thatwe're witnessing the yield curve steepen. When the U.S. economy is rebounding from a recession, it's normal for long-term yields to rise and for short-term yields to fall or flatten out. When this happens, Annaly usually experiences a widening of its NIM.\nAdditionally, Annaly almost exclusively buys agency securities. This is a fancy way of saying that the MBSs it's purchasing are backed by the federal government in the event of a default. This protection is what allows the company to utilize leverage to its advantage, thereby pumping up its profits.\nTrupanion\nLastly, companion animal health insurance company Trupanion(NASDAQ:TRUP)has all the look of an unbeatable stock to buy in a Biden bull market.\nThe pet industry may not offer flashy growth prospects like cybersecurity or cannabis, but it's arguably themost consistent growth opportunity. It's been more than a quarter of a century since year-over-year U.S. pet expenditures declined. Further, the American Pet Products Association notes that the percentage of American household owning a pet has increased from 56% in 1988 to 67% by 2019-2020. If we've learned anything about pet owners, it's that they're willing to spend big bucks to ensure the well-being of their four-legged family members.\nTrupanion, which recently lifted the hood on its first-quarter operating results, isclosing in on 1 million total enrolled pets(943,854 at the end of Q1 2021). Amazingly, this only represents a little over 1% penetration of the U.S. market. In the U.K., about 1 in 4 pet owners purchases insurance for their cat or dog. If Trupanion can achieve a similar penetration rate, its addressable market would be more than $32 billion.\nThis is a company that's spent two decades building up rapport with veterinarians and their staff at the clinical level. It's also the only major companion animal health insurance provider with software capable of handling payment to veterinarians at the time of checkout.\nThe sky is the limit for Trupanion.","news_type":1},"isVote":1,"tweetType":1,"viewCount":171,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":190218621,"gmtCreate":1620622817563,"gmtModify":1631890890062,"author":{"id":"3571619533976102","authorId":"3571619533976102","name":"TomCl","avatar":"https://static.tigerbbs.com/84c9633e30b56b9ef4c30ab8c67857b3","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3571619533976102","idStr":"3571619533976102"},"themes":[],"htmlText":"Nice","listText":"Nice","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/190218621","repostId":"1134875250","repostType":4,"repost":{"id":"1134875250","kind":"news","pubTimestamp":1620612288,"share":"https://www.laohu8.com/m/news/1134875250?lang=&edition=full","pubTime":"2021-05-10 10:04","market":"us","language":"en","title":"Cathie Wood Loads Up Another $28M Worth Of Shares In Alibaba Rival JD.Com","url":"https://stock-news.laohu8.com/highlight/detail?id=1134875250","media":"benzinga","summary":"Cathie Wood-led Ark Investment Management on Friday bought 366,879 shares, worth about $27.7 million, in JD.com Inc, a key rival to Alibaba Group Holding in the e-commerce space in China.Shares of JD.com closed 1.15% lower at $75.51 on Friday.Wood's firm has been piling up shares of Alibaba rivals, some of which now account for a better part of its holdings compared to the Jack Ma-led company, whose shareshave slumpedover 20% since October last year over troubles with the Chinese government.The ","content":"<p>Cathie Wood-led Ark Investment Management on Friday bought 366,879 shares, worth about $27.7 million, in&nbsp;<b>JD.com Inc</b>, a key rival to&nbsp;<b>Alibaba Group Holding</b>&nbsp;in the e-commerce space in China.</p><p>Shares of JD.com closed 1.15% lower at $75.51 on Friday.</p><p>Wood's firm has been piling up shares of Alibaba rivals, some of which now account for a better part of its holdings compared to the Jack Ma-led company, whose shareshave slumpedover 20% since October last year over troubles with the Chinese government.</p><p>The&nbsp;<b>ARK Innovation ETF</b>, which held about $112.5 million ahead of the trade on Friday, or 2.94% of the ETF weight, made the purchase. The stock ranks twelfth position among 47 stocks in ARKF.</p><p>The Beijing-headquartered JD.com runs one of the two massive B2C online retailers in China and is a major competitor to Alibaba-run Tmall.</p><p>Other Ark Buys On Friday:</p><ul><li><b>Coinbase Global Inc</b>COIN 2.7%</li><li><b>Veracyte Inc</b>VCYT 1.23%</li><li><b>908 Devices Inc</b>MASS 2.02%</li><li><b>Ionis Pharmaceuticals Inc</b>NASDAQINOS</li><li><b>Fate Therapeutics Inc</b>FATE 0.08%</li><li><b>CM Life Sciences II Inc</b>CMII 0.34%</li><li><b>CareDx Inc</b>CDNA 6.92%</li><li><b>Draftkings Inc</b>DKNG 6.69%</li><li><b>Unity Software Inc</b>U 1.23%</li><li><b>TuSimple Holdings</b>TSP 4.05%</li><li><b>Skillz Inc</b>SKLZ 2.01%</li><li><b>Kratos Defense &amp; Security Solutions Inc</b>KTOS 1.35%</li><li><b>One</b>AONE 0.2%</li><li><b>Iridium Communications Inc</b>IRDM 0.76%</li><li><b>Teradyne Inc</b>TER 1.77%</li><li><b>Twitter Inc</b>TWTR 0.07%</li><li><b>Nano Dimension Ltd</b>NNDM 2.93%</li><li><b>Okta Inc</b>OKTA 1.23%</li><li><b>Meituan</b>MPNGF 0.72%</li></ul><p>Ark Sells On Friday:</p><ul><li><b>Yeahka Ltd</b>YHEKF 9.94%</li><li><b>Silvergate Capital Corp</b>SI 4.33%</li><li><b>Takeda Pharmaceutical Co Ltd</b>TAK 1.5%</li><li><b>Syros Pharmaceuticals Inc</b>SYRS 5.97%</li><li><b>Roche Holding Ag</b>RHHBY 2.08%</li><li><b>Nanostring Technologies Inc</b>NSTG 3.03%</li><li><b>Lendingtree Inc</b>TREE 2.16%</li><li><b>Novartis Ag</b>NVS 0.68%</li><li><b>Pure Storage Inc</b>PSTG 2.03%</li><li><b>Baidu Inc</b>BIDU 0.41%</li><li><b>Nintendo Co Ltd</b>NTDOY 1.46%</li><li><b>Workhorse Group Inc</b>WKHS 0.31%</li><li><b>Virgin Galactic Holdings Inc (</b>NYSE: SPCE)</li><li><b>Crowdstrike Holdings Inc (</b>NASDAQ: CRWD)</li><li><b>Pinterest Inc</b>PINS 0.98%</li><li><b>Deere &amp; Co (</b>NYSE: DE)</li></ul>","source":"lsy1606299360108","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Cathie Wood Loads Up Another $28M Worth Of Shares In Alibaba Rival JD.Com</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCathie Wood Loads Up Another $28M Worth Of Shares In Alibaba Rival JD.Com\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-05-10 10:04 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.benzinga.com/etfs/sector-etfs/21/05/21027556/cathie-wood-loads-up-another-28m-worth-of-shares-in-alibaba-rival-jd-com><strong>benzinga</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Cathie Wood-led Ark Investment Management on Friday bought 366,879 shares, worth about $27.7 million, in JD.com Inc, a key rival to Alibaba Group Holding in the e-commerce space in China.Shares of ...</p>\n\n<a href=\"https://www.benzinga.com/etfs/sector-etfs/21/05/21027556/cathie-wood-loads-up-another-28m-worth-of-shares-in-alibaba-rival-jd-com\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BABA":"阿里巴巴","JD":"京东"},"source_url":"https://www.benzinga.com/etfs/sector-etfs/21/05/21027556/cathie-wood-loads-up-another-28m-worth-of-shares-in-alibaba-rival-jd-com","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1134875250","content_text":"Cathie Wood-led Ark Investment Management on Friday bought 366,879 shares, worth about $27.7 million, in JD.com Inc, a key rival to Alibaba Group Holding in the e-commerce space in China.Shares of JD.com closed 1.15% lower at $75.51 on Friday.Wood's firm has been piling up shares of Alibaba rivals, some of which now account for a better part of its holdings compared to the Jack Ma-led company, whose shareshave slumpedover 20% since October last year over troubles with the Chinese government.The ARK Innovation ETF, which held about $112.5 million ahead of the trade on Friday, or 2.94% of the ETF weight, made the purchase. The stock ranks twelfth position among 47 stocks in ARKF.The Beijing-headquartered JD.com runs one of the two massive B2C online retailers in China and is a major competitor to Alibaba-run Tmall.Other Ark Buys On Friday:Coinbase Global IncCOIN 2.7%Veracyte IncVCYT 1.23%908 Devices IncMASS 2.02%Ionis Pharmaceuticals IncNASDAQINOSFate Therapeutics IncFATE 0.08%CM Life Sciences II IncCMII 0.34%CareDx IncCDNA 6.92%Draftkings IncDKNG 6.69%Unity Software IncU 1.23%TuSimple HoldingsTSP 4.05%Skillz IncSKLZ 2.01%Kratos Defense & Security Solutions IncKTOS 1.35%OneAONE 0.2%Iridium Communications IncIRDM 0.76%Teradyne IncTER 1.77%Twitter IncTWTR 0.07%Nano Dimension LtdNNDM 2.93%Okta IncOKTA 1.23%MeituanMPNGF 0.72%Ark Sells On Friday:Yeahka LtdYHEKF 9.94%Silvergate Capital CorpSI 4.33%Takeda Pharmaceutical Co LtdTAK 1.5%Syros Pharmaceuticals IncSYRS 5.97%Roche Holding AgRHHBY 2.08%Nanostring Technologies IncNSTG 3.03%Lendingtree IncTREE 2.16%Novartis AgNVS 0.68%Pure Storage IncPSTG 2.03%Baidu IncBIDU 0.41%Nintendo Co LtdNTDOY 1.46%Workhorse Group IncWKHS 0.31%Virgin Galactic Holdings Inc (NYSE: SPCE)Crowdstrike Holdings Inc (NASDAQ: CRWD)Pinterest IncPINS 0.98%Deere & Co (NYSE: DE)","news_type":1},"isVote":1,"tweetType":1,"viewCount":203,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":105631204,"gmtCreate":1620296431108,"gmtModify":1631893073919,"author":{"id":"3571619533976102","authorId":"3571619533976102","name":"TomCl","avatar":"https://static.tigerbbs.com/84c9633e30b56b9ef4c30ab8c67857b3","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3571619533976102","idStr":"3571619533976102"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/SNDL\">$Sundial Growers Inc.(SNDL)$</a>nnice nieci","listText":"<a href=\"https://laohu8.com/S/SNDL\">$Sundial Growers Inc.(SNDL)$</a>nnice nieci","text":"$Sundial Growers Inc.(SNDL)$nnice nieci","images":[{"img":"https://static.tigerbbs.com/bede97e5c63296fec9f742656d9a64a1","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/105631204","isVote":1,"tweetType":1,"viewCount":118,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":102863555,"gmtCreate":1620194457977,"gmtModify":1631893073925,"author":{"id":"3571619533976102","authorId":"3571619533976102","name":"TomCl","avatar":"https://static.tigerbbs.com/84c9633e30b56b9ef4c30ab8c67857b3","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3571619533976102","idStr":"3571619533976102"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/SNDL\">$Sundial Growers Inc.(SNDL)$</a>nive nice","listText":"<a href=\"https://laohu8.com/S/SNDL\">$Sundial Growers Inc.(SNDL)$</a>nive nice","text":"$Sundial Growers Inc.(SNDL)$nive nice","images":[{"img":"https://static.tigerbbs.com/0b2eb12693b8f6ecf14229e9a566de49","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/102863555","isVote":1,"tweetType":1,"viewCount":292,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":325940836,"gmtCreate":1615859515925,"gmtModify":1703494085397,"author":{"id":"3571619533976102","authorId":"3571619533976102","name":"TomCl","avatar":"https://static.tigerbbs.com/84c9633e30b56b9ef4c30ab8c67857b3","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3571619533976102","idStr":"3571619533976102"},"themes":[],"htmlText":"Nice","listText":"Nice","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/325940836","repostId":"1124726208","repostType":4,"repost":{"id":"1124726208","kind":"news","pubTimestamp":1615854446,"share":"https://www.laohu8.com/m/news/1124726208?lang=&edition=full","pubTime":"2021-03-16 08:27","market":"us","language":"en","title":"Elon Musk Is Now the ‘Technoking’ of Tesla. What’s Behind the Name.","url":"https://stock-news.laohu8.com/highlight/detail?id=1124726208","media":"Barrons","summary":"Tesla’s Elon Musk isn’t only a CEO. On Monday, he became a king of sorts.The electric vehicle pioneer toldthe Securities and Exchange Commissionthat founderMuskwill add the title Technoking of Tesla . CFO Zach Kirkhorn is getting another one, too: Master of Coin.In the SEC 8-K filing, Kirkhorn adds: “Elon and Zach will also maintain their respective positions as Chief Executive Officer and Chief Financial Officer.”The new titles might reflect the men’s decision to put some of Tesla’s cash into B","content":"<p>Tesla’s Elon Musk isn’t only a CEO. On Monday, he became a king of sorts.</p><p>The electric vehicle pioneer toldthe Securities and Exchange Commissionthat founderMuskwill add the title Technoking of Tesla (ticker: TSLA). CFO Zach Kirkhorn is getting another one, too: Master of Coin.</p><p>In the SEC 8-K filing, Kirkhorn adds: “Elon and Zach will also maintain their respective positions as Chief Executive Officer and Chief Financial Officer.”</p><p>An 8-K form is what companies file to notify shareholders of important information, such as earnings news releases, management appointments and corporate acquisitions.</p><p>The new titles might reflect the men’s decision to put some of Tesla’s cash&nbsp;into Bitcoin. The cryptocurrency hit $60,000 over the weekend, making the EV maker more than&nbsp;$1 billion&nbsp;on its initial $1.5 billion buy. Tesla invested back when Bitcoin was about $33,000.</p><p>Bitcoin has fallen back in Monday trading to about $56,000, but is still up more than 90% year to date and more than 20% in March.</p><p>Musk spent part of his weekend tweeting about another of his favorite cryptocurrencies, Dogecoin, which is up to a little more than a nickel a Dogecoin—roughly about 1,300% year to date.</p><p>Institutional investors are playing a major role in Bitcoin's recent uptick. Here's why, and what it means for the future.</p><p>The Technoking and Master of Coin titles fall in line with Tesla’s offbeat approach. Musk has turned Tesla into the most valuable car company in the world by, essentially, paying no attention to what traditional automotive companies and analysts say.</p><p>Still, the news isn’t doing much to Tesla stock, which is up about 2%&nbsp;on&nbsp;Monday.S&amp;P 500&nbsp;and&nbsp;Dow Jones Industrial Average&nbsp;futures are up about 0.7% and 0.5%, respectively.</p><p>Investors are really waiting for the Federal Reserve to comment on interest rates later in the week. The U.S. 10 Year Treasury bond yield is up to about 1.6% from 1.2% only a few weeks back. The rapid rise has hit growth stocks, including Tesla shares. The&nbsp;Nasdaq Composite,home to many richly valued, high-growth stocks, is down about 5% since Feb. 16, when the index hit an all-time high. The Dow is up about 4% over the same period.</p><p>Tesla stock is down about 13% since then. Higher rate&nbsp;shit high-growth stocks&nbsp;harder than others. They make it more expensive to finance growth like what Mush is targeting—vehicle delivery growth a year on average for the foreseeable future.</p><p>What’s more, growth companies generate cash far in the future which is worth a little less, relatively speaking, when investors have other options to earn higher rates of interest today.</p>","source":"lsy1601382232898","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Elon Musk Is Now the ‘Technoking’ of Tesla. What’s Behind the Name.</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nElon Musk Is Now the ‘Technoking’ of Tesla. What’s Behind the Name.\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-03-16 08:27 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.barrons.com/articles/teslas-elon-musk-adds-a-title-and-tells-the-sec-about-it-51615816265?mod=hp_DAY_4><strong>Barrons</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Tesla’s Elon Musk isn’t only a CEO. On Monday, he became a king of sorts.The electric vehicle pioneer toldthe Securities and Exchange Commissionthat founderMuskwill add the title Technoking of Tesla (...</p>\n\n<a href=\"https://www.barrons.com/articles/teslas-elon-musk-adds-a-title-and-tells-the-sec-about-it-51615816265?mod=hp_DAY_4\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TSLA":"特斯拉"},"source_url":"https://www.barrons.com/articles/teslas-elon-musk-adds-a-title-and-tells-the-sec-about-it-51615816265?mod=hp_DAY_4","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1124726208","content_text":"Tesla’s Elon Musk isn’t only a CEO. On Monday, he became a king of sorts.The electric vehicle pioneer toldthe Securities and Exchange Commissionthat founderMuskwill add the title Technoking of Tesla (ticker: TSLA). CFO Zach Kirkhorn is getting another one, too: Master of Coin.In the SEC 8-K filing, Kirkhorn adds: “Elon and Zach will also maintain their respective positions as Chief Executive Officer and Chief Financial Officer.”An 8-K form is what companies file to notify shareholders of important information, such as earnings news releases, management appointments and corporate acquisitions.The new titles might reflect the men’s decision to put some of Tesla’s cash into Bitcoin. The cryptocurrency hit $60,000 over the weekend, making the EV maker more than $1 billion on its initial $1.5 billion buy. Tesla invested back when Bitcoin was about $33,000.Bitcoin has fallen back in Monday trading to about $56,000, but is still up more than 90% year to date and more than 20% in March.Musk spent part of his weekend tweeting about another of his favorite cryptocurrencies, Dogecoin, which is up to a little more than a nickel a Dogecoin—roughly about 1,300% year to date.Institutional investors are playing a major role in Bitcoin's recent uptick. Here's why, and what it means for the future.The Technoking and Master of Coin titles fall in line with Tesla’s offbeat approach. Musk has turned Tesla into the most valuable car company in the world by, essentially, paying no attention to what traditional automotive companies and analysts say.Still, the news isn’t doing much to Tesla stock, which is up about 2% on Monday.S&P 500 and Dow Jones Industrial Average futures are up about 0.7% and 0.5%, respectively.Investors are really waiting for the Federal Reserve to comment on interest rates later in the week. The U.S. 10 Year Treasury bond yield is up to about 1.6% from 1.2% only a few weeks back. The rapid rise has hit growth stocks, including Tesla shares. The Nasdaq Composite,home to many richly valued, high-growth stocks, is down about 5% since Feb. 16, when the index hit an all-time high. The Dow is up about 4% over the same period.Tesla stock is down about 13% since then. Higher rate shit high-growth stocks harder than others. They make it more expensive to finance growth like what Mush is targeting—vehicle delivery growth a year on average for the foreseeable future.What’s more, growth companies generate cash far in the future which is worth a little less, relatively speaking, when investors have other options to earn higher rates of interest today.","news_type":1},"isVote":1,"tweetType":1,"viewCount":50,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":329901987,"gmtCreate":1615195520449,"gmtModify":1703485469277,"author":{"id":"3571619533976102","authorId":"3571619533976102","name":"TomCl","avatar":"https://static.tigerbbs.com/84c9633e30b56b9ef4c30ab8c67857b3","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3571619533976102","idStr":"3571619533976102"},"themes":[],"htmlText":"Interesting","listText":"Interesting","text":"Interesting","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/329901987","repostId":"2117651365","repostType":4,"isVote":1,"tweetType":1,"viewCount":39,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":320469092,"gmtCreate":1615168716916,"gmtModify":1703485110166,"author":{"id":"3571619533976102","authorId":"3571619533976102","name":"TomCl","avatar":"https://static.tigerbbs.com/84c9633e30b56b9ef4c30ab8c67857b3","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3571619533976102","idStr":"3571619533976102"},"themes":[],"htmlText":"Nice","listText":"Nice","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/320469092","repostId":"2117639609","repostType":4,"repost":{"id":"2117639609","kind":"news","pubTimestamp":1614957600,"share":"https://www.laohu8.com/m/news/2117639609?lang=&edition=full","pubTime":"2021-03-05 23:20","market":"us","language":"en","title":"What's the Outlook for Intuitive Surgical?","url":"https://stock-news.laohu8.com/highlight/detail?id=2117639609","media":"Jason Hawthorne","summary":"Competition is heating up, but the company's market leadership remains unchallenged.","content":"<p>After being relegated to science fiction for most of the 20th century, robots have been more visible over the past two decades. Although most real-world applications so far have been industrial, <b>Intuitive</b> <b>Surgical</b> (NASDAQ:ISRG) has been slowly changing that. The company's da Vinci surgical systems only assist trained humans, but they have become synonymous with the term \"robotic surgery.\"</p><p>After so much success, interested investors will want to determine whether the future can be as bright as the past, or if the combination of COVID, regulatory hurdles, and competition will chip away at the dominance this company has established since going public in 2000.</p><p><img src=\"https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F615724%2Fgettyimages-1218322943.jpg&amp;w=700&amp;op=resize\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\"></p><p>The arms of a surgical robot. Image source: Getty Images.</p><p><b>Managing through COVID-19</b></p><p>Early during the pandemic, when hospitals were stopping elective procedures to dedicate resources to patients with COVID-19, the company's sales tumbled. Year-over-year revenue declined 22% in the second quarter of 2020 on 19% fewer procedures.</p><p>Procedures and revenue rebounded slightly in the following quarter, up 7% and down 4.5%, respectively, compared to 2019. The fourth quarter finally saw year-over-year revenue growth of 4%, but management remained cautious.</p><p>Citing a holiday rise in COVID-19 cases, CEO Gary Guthart pointed to a lag in diagnostic cases at hospitals and weak surgery data spilling over from December into January as an indication that the sales of da Vinci systems would take several quarters to normalize. With fewer cases, utilization of existing machines will remain low, delaying the need to add capacity.</p><p>Although this is definitely a concern, it's a temporary <a href=\"https://laohu8.com/S/AONE\">one</a>. By the end of 2021, orders and installations should be back to normal. System growth has averaged 12% a year over the past decade and 28% for the three years prior to the pandemic. Investors are hoping the return to normal comes sooner rather than later.</p><p><b>A changing regulatory landscape</b></p><p>In recent quarters, management has become much more vocal about a shifting regulatory landscape in the U.S. and Europe, and the requirement for more data than ever before prior to approval. Guthart has said the requirements have stabilized at a level higher than in past years. Although it's a short-term nuisance, this change stands to benefit incumbents like Intuitive over time, because existing systems will sit on the market longer while innovations wait for approval.</p><p>One region where the company has drastically different regulatory experiences is Asia. Guthart has repeatedly cited South Korea as being quick to allow innovative products to market, while China's centrally managed system is more cautious. System sales in the region grew 60% from 2018 to 2019 before falling off during 2020 due to the pandemic. Products launched in China must have a longer history of performance because that country's version of the Food and Drug Administration handles first-generation products very cautiously. Regardless, the company remains excited about its joint venture with Chinese company Fosun Pharma and expects strong, if somewhat turbulent, demand over time.</p><p><b>Defending the moat</b></p><p>One of the risks in China is the launch of companies trying to bring competitive surgical systems to market. This has already happened in South Korea. That country's embrace of innovation is a double-edged sword for Intuitive -- South Korea's first approved surgical robot was made by <b>Meere</b> back in 2017.</p><p>Asia isn't the only region where companies are tired of Intuitive reaping the lion's share of the robotic surgery opportunity. Closer to home, the company faces long-awaited challenges from device makers <b>Medtronic</b> (NYSE:MDT) and <b>Johnson</b> <b>&amp;</b> <b>Johnson</b> (NYSE:JNJ).</p><p>Medtronic made its intentions clear by acquiring spine surgery innovator Mazor Robotics in 2018. It is planning a launch of its Hugo surgical system outside the U.S. to collect data, and expects to submit for an investigational device exemption from the FDA in the next month. That designation would allow the device to be used in a clinical study.</p><p>Johnson &amp; Johnson has a not-so-secret weapon in the battle for the robotic surgery market: the founder of Intuitive Surgical. Dr. Fred Moll, who practically invented the industry when he founded Intuitive in 1995, is chief development officer at the company's devices unit. With his guidance, the healthcare giant plans to commercialize three robotic platforms it gained via acquisition.</p><p>First, the Velys platform is for total knee replacements. This is the type of high-volume, repeatable procedure that is ripe for robotic assistance. But it's a threat to <b>Stryker</b> and <b>Smith</b> <b>&amp;</b> <b>Nephew</b>, not Intuitive.</p><p>Second, the Monarch platform is for a procedure that lets doctors inspect the lungs and air passages. It will eventually be used for lung biopsies, but Intuitive is already staking a claim here with its Ion system. In fact, Intuitive received FDA approval for the procedure in the first quarter of 2019.</p><p>And third, Johnson &amp; Johnson's Ottava general surgery system was introduced in November after much anticipation. The device integrates with an operating table and has six arms, several more than systems currently on the market. The goal is flexibility. If Ottava can perform many types of operations, it will help hospitals avoid buying multiple robots, each with a different purpose. The system is unlikely to come to market before 2024.</p><p><b>Clear skies, with a few clouds on the horizon</b></p><p>Despite some regulatory red tape at home and upstart competition abroad, the path for Intuitive Surgical to continue its decades of growth seems clear. The company is well ahead of the competition with nearly 6,000 surgical systems already installed around the globe, and it will be hard for competitors to replace them. That is especially true as innovation in da Vinci systems, instrumentation, and capability continues to increase both machine utilization and company sales.</p><p>As a shareholder, I'll be watching the regulatory progress of the competing systems. But changes in the approval process have only made it harder for the competition to get a foothold. With no imminent threats for at least the next few years, the shares will stay tucked away in a part of my portfolio as far from the sell button as any I own. For those looking to add the stock to their own portfolios, the recent market volatility may have provided the opportunity they've been waiting for.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>What's the Outlook for Intuitive Surgical?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhat's the Outlook for Intuitive Surgical?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-03-05 23:20 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/03/05/whats-the-outlook-for-intuitive-surgical/><strong>Jason Hawthorne</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>After being relegated to science fiction for most of the 20th century, robots have been more visible over the past two decades. Although most real-world applications so far have been industrial, ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/03/05/whats-the-outlook-for-intuitive-surgical/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F615724%2Fgettyimages-1218322943.jpg&amp;w=700&amp;op=resize","relate_stocks":{"ISRG":"直觉外科公司"},"source_url":"https://www.fool.com/investing/2021/03/05/whats-the-outlook-for-intuitive-surgical/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2117639609","content_text":"After being relegated to science fiction for most of the 20th century, robots have been more visible over the past two decades. Although most real-world applications so far have been industrial, Intuitive Surgical (NASDAQ:ISRG) has been slowly changing that. The company's da Vinci surgical systems only assist trained humans, but they have become synonymous with the term \"robotic surgery.\"After so much success, interested investors will want to determine whether the future can be as bright as the past, or if the combination of COVID, regulatory hurdles, and competition will chip away at the dominance this company has established since going public in 2000.The arms of a surgical robot. Image source: Getty Images.Managing through COVID-19Early during the pandemic, when hospitals were stopping elective procedures to dedicate resources to patients with COVID-19, the company's sales tumbled. Year-over-year revenue declined 22% in the second quarter of 2020 on 19% fewer procedures.Procedures and revenue rebounded slightly in the following quarter, up 7% and down 4.5%, respectively, compared to 2019. The fourth quarter finally saw year-over-year revenue growth of 4%, but management remained cautious.Citing a holiday rise in COVID-19 cases, CEO Gary Guthart pointed to a lag in diagnostic cases at hospitals and weak surgery data spilling over from December into January as an indication that the sales of da Vinci systems would take several quarters to normalize. With fewer cases, utilization of existing machines will remain low, delaying the need to add capacity.Although this is definitely a concern, it's a temporary one. By the end of 2021, orders and installations should be back to normal. System growth has averaged 12% a year over the past decade and 28% for the three years prior to the pandemic. Investors are hoping the return to normal comes sooner rather than later.A changing regulatory landscapeIn recent quarters, management has become much more vocal about a shifting regulatory landscape in the U.S. and Europe, and the requirement for more data than ever before prior to approval. Guthart has said the requirements have stabilized at a level higher than in past years. Although it's a short-term nuisance, this change stands to benefit incumbents like Intuitive over time, because existing systems will sit on the market longer while innovations wait for approval.One region where the company has drastically different regulatory experiences is Asia. Guthart has repeatedly cited South Korea as being quick to allow innovative products to market, while China's centrally managed system is more cautious. System sales in the region grew 60% from 2018 to 2019 before falling off during 2020 due to the pandemic. Products launched in China must have a longer history of performance because that country's version of the Food and Drug Administration handles first-generation products very cautiously. Regardless, the company remains excited about its joint venture with Chinese company Fosun Pharma and expects strong, if somewhat turbulent, demand over time.Defending the moatOne of the risks in China is the launch of companies trying to bring competitive surgical systems to market. This has already happened in South Korea. That country's embrace of innovation is a double-edged sword for Intuitive -- South Korea's first approved surgical robot was made by Meere back in 2017.Asia isn't the only region where companies are tired of Intuitive reaping the lion's share of the robotic surgery opportunity. Closer to home, the company faces long-awaited challenges from device makers Medtronic (NYSE:MDT) and Johnson & Johnson (NYSE:JNJ).Medtronic made its intentions clear by acquiring spine surgery innovator Mazor Robotics in 2018. It is planning a launch of its Hugo surgical system outside the U.S. to collect data, and expects to submit for an investigational device exemption from the FDA in the next month. That designation would allow the device to be used in a clinical study.Johnson & Johnson has a not-so-secret weapon in the battle for the robotic surgery market: the founder of Intuitive Surgical. Dr. Fred Moll, who practically invented the industry when he founded Intuitive in 1995, is chief development officer at the company's devices unit. With his guidance, the healthcare giant plans to commercialize three robotic platforms it gained via acquisition.First, the Velys platform is for total knee replacements. This is the type of high-volume, repeatable procedure that is ripe for robotic assistance. But it's a threat to Stryker and Smith & Nephew, not Intuitive.Second, the Monarch platform is for a procedure that lets doctors inspect the lungs and air passages. It will eventually be used for lung biopsies, but Intuitive is already staking a claim here with its Ion system. In fact, Intuitive received FDA approval for the procedure in the first quarter of 2019.And third, Johnson & Johnson's Ottava general surgery system was introduced in November after much anticipation. The device integrates with an operating table and has six arms, several more than systems currently on the market. The goal is flexibility. If Ottava can perform many types of operations, it will help hospitals avoid buying multiple robots, each with a different purpose. The system is unlikely to come to market before 2024.Clear skies, with a few clouds on the horizonDespite some regulatory red tape at home and upstart competition abroad, the path for Intuitive Surgical to continue its decades of growth seems clear. The company is well ahead of the competition with nearly 6,000 surgical systems already installed around the globe, and it will be hard for competitors to replace them. That is especially true as innovation in da Vinci systems, instrumentation, and capability continues to increase both machine utilization and company sales.As a shareholder, I'll be watching the regulatory progress of the competing systems. But changes in the approval process have only made it harder for the competition to get a foothold. With no imminent threats for at least the next few years, the shares will stay tucked away in a part of my portfolio as far from the sell button as any I own. For those looking to add the stock to their own portfolios, the recent market volatility may have provided the opportunity they've been waiting for.","news_type":1},"isVote":1,"tweetType":1,"viewCount":26,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":320460591,"gmtCreate":1615168702213,"gmtModify":1703485109821,"author":{"id":"3571619533976102","authorId":"3571619533976102","name":"TomCl","avatar":"https://static.tigerbbs.com/84c9633e30b56b9ef4c30ab8c67857b3","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3571619533976102","idStr":"3571619533976102"},"themes":[],"htmlText":"Nice","listText":"Nice","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/320460591","repostId":"1169596583","repostType":4,"repost":{"id":"1169596583","kind":"news","weMediaInfo":{"introduction":"为用户提供金融资讯、行情、数据，旨在帮助投资者理解世界，做投资决策。","home_visible":1,"media_name":"老虎资讯综合","id":"102","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1614958557,"share":"https://www.laohu8.com/m/news/1169596583?lang=&edition=full","pubTime":"2021-03-05 23:35","market":"us","language":"en","title":"Palantir plunged more than 13%","url":"https://stock-news.laohu8.com/highlight/detail?id=1169596583","media":"老虎资讯综合","summary":"(March 5)&nbsp;Palantir plunged more than 13%.","content":"<p>(March 5)&nbsp;Palantir plunged more than 13%.</p><p><img src=\"https://static.tigerbbs.com/13f756ec57cca85c31b6be070941d7c1\" tg-width=\"1059\" tg-height=\"499\" referrerpolicy=\"no-referrer\"></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Palantir plunged more than 13%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPalantir plunged more than 13%\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/102\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">老虎资讯综合 </p>\n<p class=\"h-time\">2021-03-05 23:35</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>(March 5)&nbsp;Palantir plunged more than 13%.</p><p><img src=\"https://static.tigerbbs.com/13f756ec57cca85c31b6be070941d7c1\" tg-width=\"1059\" tg-height=\"499\" referrerpolicy=\"no-referrer\"></p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PLTR":"Palantir Technologies Inc."},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1169596583","content_text":"(March 5) Palantir plunged more than 13%.","news_type":1},"isVote":1,"tweetType":1,"viewCount":215,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":365633654,"gmtCreate":1614733495878,"gmtModify":1703480415259,"author":{"id":"3571619533976102","authorId":"3571619533976102","name":"TomCl","avatar":"https://static.tigerbbs.com/84c9633e30b56b9ef4c30ab8c67857b3","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3571619533976102","idStr":"3571619533976102"},"themes":[],"htmlText":"Interesting","listText":"Interesting","text":"Interesting","images":[{"img":"https://static.tigerbbs.com/b30618556d21a99e71177bbe50075def","width":"1080","height":"2663"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/365633654","isVote":1,"tweetType":1,"viewCount":123,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":361808646,"gmtCreate":1614217655485,"gmtModify":1634550663410,"author":{"id":"3571619533976102","authorId":"3571619533976102","name":"TomCl","avatar":"https://static.tigerbbs.com/84c9633e30b56b9ef4c30ab8c67857b3","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3571619533976102","idStr":"3571619533976102"},"themes":[],"htmlText":"Interesting","listText":"Interesting","text":"Interesting","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/361808646","repostId":"2114392599","repostType":2,"repost":{"id":"2114392599","kind":"highlight","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1614212913,"share":"https://www.laohu8.com/m/news/2114392599?lang=&edition=full","pubTime":"2021-02-25 08:28","market":"sh","language":"en","title":"Asian open higher as Fed's Powell nixes inflation fears","url":"https://stock-news.laohu8.com/highlight/detail?id=2114392599","media":"Reuters","summary":"MIAMI, Feb 24 (Reuters) - Asian stocks perked up on Thursday after U.S. Federal Reserve Chair Jerome","content":"<p>MIAMI, Feb 24 (Reuters) - Asian stocks perked up on Thursday after U.S. Federal Reserve Chair Jerome Powell reaffirmed interest rates would stay low, calming market fears that higher inflation might prompt the central bank to tighten the monetary spigot.</p>\n<p>\"The dovish influence from the Fed is going to continue to resonate over in Asia. That's really good for emerging market assets when we've got a really good impulse from the Fed,\" said Stephen Innes, chief global markets strategist at Axi.</p>\n<p>Australia's S&amp;P/ASX 200 rose 0.90% in early trade while Japan's Nikkei 225 added 1.37%. Hong Kong's Hang Seng index futures rose 0.92%.</p>\n<p>In a second day of testimony in Washington, Powell reiterated the Fed's promise to get the U.S. economy back to full employment and to not worry about inflation unless prices rose in a persistent and troubling way.</p>\n<p>Crude oil climbed to fresh 13-month highs after U.S. government data showed a drop in crude output as a deep freeze disrupted production last week.</p>\n<p>Gold prices struggled for traction as elevated Treasury yields eroded the allure of bullion as an inflation hedge.</p>\n<p>The dollar hit fresh three-year lows against the pound and commodity-linked currencies including the Canadian, Australian and New Zealand dollars, which are expected to benefit from a pick-up in global trade as growth rebounds.</p>\n<p>MSCI's gauge of stocks across the globe gained 0.12%, as rising stocks on Wall Street pushed the global benchmark to reverse early losses.</p>\n<p>The Dow Jones Industrial Average set a record high rising 1.35% to 31,961.86 while the S&amp;P 500 gained 1.14%. The Nasdaq index, which fell as much as 1.3% earlier in the session, regained its footing by early afternoon and closed up 0.99%.</p>\n<p>Shares of GameStop Corp, at the center of a volatile retail trading frenzy moves in late January, more than doubled in price in late trading and continued to soar in heavy, post-market trade.</p>\n<p>The U.S. Food and Drug Administration said on Wednesday Johnson &amp; Johnson's <a href=\"https://laohu8.com/S/AONE\">one</a>-dose COVID-19 vaccine appeared safe and effective in trials, paving the way for its approval for emergency use as soon as this week.</p>\n<p>Johnson &amp; Johnson rose 1.3% following the news, seen as another boost to a strong recovery.</p>\n<p>The dollar index fell 0.083%, with the euro up 0.02% to $1.2167. The Japanese yen weakened 0.03% versus the greenback at 105.91 per dollar.</p>\n<p>Oil prices rose after U.S. government data showed a drop in crude output as a deep freeze disrupted production last week.</p>\n<p>U.S. crude recently rose 0.3% to $63.41 per barrel and Brent was at $67.31, up 2.97% on the day.</p>\n<p>Spot gold dropped 0.1% to $1,802.72 an ounce. U.S. gold futures gained 0.30% to $1,802.00 an ounce.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Asian open higher as Fed's Powell nixes inflation fears</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAsian open higher as Fed's Powell nixes inflation fears\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-02-25 08:28</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>MIAMI, Feb 24 (Reuters) - Asian stocks perked up on Thursday after U.S. Federal Reserve Chair Jerome Powell reaffirmed interest rates would stay low, calming market fears that higher inflation might prompt the central bank to tighten the monetary spigot.</p>\n<p>\"The dovish influence from the Fed is going to continue to resonate over in Asia. That's really good for emerging market assets when we've got a really good impulse from the Fed,\" said Stephen Innes, chief global markets strategist at Axi.</p>\n<p>Australia's S&amp;P/ASX 200 rose 0.90% in early trade while Japan's Nikkei 225 added 1.37%. Hong Kong's Hang Seng index futures rose 0.92%.</p>\n<p>In a second day of testimony in Washington, Powell reiterated the Fed's promise to get the U.S. economy back to full employment and to not worry about inflation unless prices rose in a persistent and troubling way.</p>\n<p>Crude oil climbed to fresh 13-month highs after U.S. government data showed a drop in crude output as a deep freeze disrupted production last week.</p>\n<p>Gold prices struggled for traction as elevated Treasury yields eroded the allure of bullion as an inflation hedge.</p>\n<p>The dollar hit fresh three-year lows against the pound and commodity-linked currencies including the Canadian, Australian and New Zealand dollars, which are expected to benefit from a pick-up in global trade as growth rebounds.</p>\n<p>MSCI's gauge of stocks across the globe gained 0.12%, as rising stocks on Wall Street pushed the global benchmark to reverse early losses.</p>\n<p>The Dow Jones Industrial Average set a record high rising 1.35% to 31,961.86 while the S&amp;P 500 gained 1.14%. The Nasdaq index, which fell as much as 1.3% earlier in the session, regained its footing by early afternoon and closed up 0.99%.</p>\n<p>Shares of GameStop Corp, at the center of a volatile retail trading frenzy moves in late January, more than doubled in price in late trading and continued to soar in heavy, post-market trade.</p>\n<p>The U.S. Food and Drug Administration said on Wednesday Johnson &amp; Johnson's <a href=\"https://laohu8.com/S/AONE\">one</a>-dose COVID-19 vaccine appeared safe and effective in trials, paving the way for its approval for emergency use as soon as this week.</p>\n<p>Johnson &amp; Johnson rose 1.3% following the news, seen as another boost to a strong recovery.</p>\n<p>The dollar index fell 0.083%, with the euro up 0.02% to $1.2167. The Japanese yen weakened 0.03% versus the greenback at 105.91 per dollar.</p>\n<p>Oil prices rose after U.S. government data showed a drop in crude output as a deep freeze disrupted production last week.</p>\n<p>U.S. crude recently rose 0.3% to $63.41 per barrel and Brent was at $67.31, up 2.97% on the day.</p>\n<p>Spot gold dropped 0.1% to $1,802.72 an ounce. U.S. gold futures gained 0.30% to $1,802.00 an ounce.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"159934":"黄金ETF","518880":"黄金ETF",".IXIC":"NASDAQ Composite","GLD":"SPDR黄金ETF",".SPX":"S&P 500 Index","USO":"美国原油ETF","DDG":"ProShares做空石油与天然气ETF","DUST":"二倍做空黄金矿业指数ETF-Direxion","SQQQ":"纳指三倍做空ETF","DOG":"道指反向ETF","PSQ":"纳指反向ETF","UCO":"二倍做多彭博原油ETF","DXD":"道指两倍做空ETF","FXE":"欧元做多ETF-CurrencyShares","QQQ":"纳指100ETF","DUG":"二倍做空石油与天然气ETF(ProShares)","DJX":"1/100道琼斯","GDX":"黄金矿业ETF-VanEck","SDOW":"道指三倍做空ETF-ProShares","DDM":"道指两倍做多ETF","EUO":"欧元ETF-ProShares两倍做空","GME":"游戏驿站","NUGT":"二倍做多黄金矿业指数ETF-Direxion","TQQQ":"纳指三倍做多ETF","SCO":"二倍做空彭博原油指数ETF","JNJ":"强生","YCS":"日元ETF-ProShares两倍做空","FXY":"日元ETF-CurrencyShares","DWT":"三倍做空原油ETN","QLD":"纳指两倍做多ETF","UDOW":"道指三倍做多ETF-ProShares","QID":"纳指两倍做空ETF","IAU":"黄金信托ETF(iShares)",".DJI":"道琼斯"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2114392599","content_text":"MIAMI, Feb 24 (Reuters) - Asian stocks perked up on Thursday after U.S. Federal Reserve Chair Jerome Powell reaffirmed interest rates would stay low, calming market fears that higher inflation might prompt the central bank to tighten the monetary spigot.\n\"The dovish influence from the Fed is going to continue to resonate over in Asia. That's really good for emerging market assets when we've got a really good impulse from the Fed,\" said Stephen Innes, chief global markets strategist at Axi.\nAustralia's S&P/ASX 200 rose 0.90% in early trade while Japan's Nikkei 225 added 1.37%. Hong Kong's Hang Seng index futures rose 0.92%.\nIn a second day of testimony in Washington, Powell reiterated the Fed's promise to get the U.S. economy back to full employment and to not worry about inflation unless prices rose in a persistent and troubling way.\nCrude oil climbed to fresh 13-month highs after U.S. government data showed a drop in crude output as a deep freeze disrupted production last week.\nGold prices struggled for traction as elevated Treasury yields eroded the allure of bullion as an inflation hedge.\nThe dollar hit fresh three-year lows against the pound and commodity-linked currencies including the Canadian, Australian and New Zealand dollars, which are expected to benefit from a pick-up in global trade as growth rebounds.\nMSCI's gauge of stocks across the globe gained 0.12%, as rising stocks on Wall Street pushed the global benchmark to reverse early losses.\nThe Dow Jones Industrial Average set a record high rising 1.35% to 31,961.86 while the S&P 500 gained 1.14%. The Nasdaq index, which fell as much as 1.3% earlier in the session, regained its footing by early afternoon and closed up 0.99%.\nShares of GameStop Corp, at the center of a volatile retail trading frenzy moves in late January, more than doubled in price in late trading and continued to soar in heavy, post-market trade.\nThe U.S. Food and Drug Administration said on Wednesday Johnson & Johnson's one-dose COVID-19 vaccine appeared safe and effective in trials, paving the way for its approval for emergency use as soon as this week.\nJohnson & Johnson rose 1.3% following the news, seen as another boost to a strong recovery.\nThe dollar index fell 0.083%, with the euro up 0.02% to $1.2167. The Japanese yen weakened 0.03% versus the greenback at 105.91 per dollar.\nOil prices rose after U.S. government data showed a drop in crude output as a deep freeze disrupted production last week.\nU.S. crude recently rose 0.3% to $63.41 per barrel and Brent was at $67.31, up 2.97% on the day.\nSpot gold dropped 0.1% to $1,802.72 an ounce. U.S. gold futures gained 0.30% to $1,802.00 an ounce.","news_type":1},"isVote":1,"tweetType":1,"viewCount":39,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"lives":[]}